Misuse of Drugs Regulations

Misuse of Drugs Act

(CHAPTER 185, Section 44)

Rg 1

G.N. No. S 234/1973

REVISED EDITION 1999

(1st July 1999)

[7th July 1973]

PART I

GENERAL

Citation

1. These Regulations may be cited as the Misuse of Drugs Regulations.

Definitions

2.—(1) In these Regulations, unless the context otherwise requires —

“collaborative practice agreement” and “collaborative prescribing practitioner” have the meanings given by regulation 2 of the Healthcare Services (Collaborative Prescribing Service) Regulations 2023 (G.N. No. S 398/2023);

[S 399/2023 wef 26/06/2023]

“dentist” means a person registered under the Dentists Act (Cap. 76) and whose name appears in the first division of the register of dentists kept under that Act;

“DSO National Laboratories” means the company incorporated under the Companies Act 1967 as DSO National Laboratories (UEN 199701777M);

[S 796/2025 wef 15/12/2025]

“hospital” includes a clinic, outpatient dispensary, nursing home or other medical institution;

“inspector” means an inspector appointed by the Minister under regulation 21;

“medical practitioner” means a person registered under the Medical Registration Act (Cap. 174);

“medicinal opium” means opium which has undergone the process necessary to adapt it for medicinal use in accordance with the requirements of the British Pharmacopoeia, whether it is in the form of powder or is granulated or is in any other form, and whether it is or is not mixed with neutral substances;

“nurse” means a person registered as a nurse under the provisions of any written law for the time being in force relating to the registration of nurses;

“pharmacist” means a person registered under the Pharmacists Registration Act (Cap. 230);

“practitioner” means a medical practitioner, dentist or veterinary surgeon;

“prescription” means a prescription issued by a medical practitioner for the medical treatment of a single individual, by a dentist for the dental treatment of a single individual, by a collaborative prescribing practitioner practising in accordance with the collaborative practice agreement applicable to him or by a veterinary surgeon for the purposes of animal treatment;

[S 939/2021 wef 15/12/2021]

“register” means a bound book and does not include any form of loose leaf register or card index;

“veterinary surgeon” means a person normally resident in Singapore who holds the diploma of membership of the Royal College of Veterinary Surgeons of England or the diploma of any other veterinary institution or examining body approved by the Minister.

(2) In these Regulations, any reference to a regulation or Schedule shall be construed as a reference to a regulation contained in these Regulations or, as the case may be, to a Schedule thereto; and any reference in a regulation or Schedule to a paragraph shall be construed as a reference to a paragraph of that regulation or Schedule.

PART II

EXEMPTIONS FROM CERTAIN PROVISIONS OF ACT

Exceptions for drugs in First Schedule

3. Sections 5, 6, 7 and 8 of the Act do not apply in relation to the controlled drugs specified in the First Schedule.

[S 939/2021 wef 15/12/2021]

Licences to import, export, manufacture, etc., controlled drugs

4.—(1) Where any person is authorised by a licence issued by the Minister, or such person as he may appoint, under this regulation which is for the time being in force to import or export, manufacture, supply, offer to supply or have in his possession any controlled drug, it shall not be unlawful for that person to import or export, manufacture, supply, offer to supply or have in his possession that drug in accordance with the terms of the licence and in compliance with the conditions attached to the licence.

[S 436/2000 wef 02/10/2000]

(2) The fees for licences issued under paragraph (1) shall be as set out in the Seventh Schedule.

General authority to possess and supply controlled drugs

5.—(1) Despite section 8 of the Act, any of the following persons is permitted by these Regulations to lawfully have any controlled drug in his possession:

(a)	an officer when acting in the course of his duty and in the exercise of his powers under the Act;
(b)	a person engaged in the business of a carrier when acting in the course of that business;
(c)	a person engaged in the work of any laboratory to which the drug has been sent for forensic examination when acting in the course of his duty as a person so engaged;
(d)	a person engaged in conveying the drug to a person authorised by these Regulations to have it in his possession.

(2) Despite section 5 of the Act, any of the persons mentioned in paragraph (1) may, when acting in that capacity, supply or offer to supply any controlled drug to any person who is permitted by these Regulations to lawfully have that drug in his possession.

[S 939/2021 wef 15/12/2021]

Administration of drugs in Second and Third Schedules

6.—(1) Only a medical practitioner, a dentist, or a collaborative prescribing practitioner practising in accordance with the collaborative practice agreement applicable to him, may administer to a patient any drug specified in the Second or Third Schedule.

(2) Any person other than a medical practitioner, a dentist, or a collaborative prescribing practitioner, may administer any drug specified in the Second or Third Schedule to a patient, only in accordance with the directions of —

(a)	a medical practitioner;
(b)	a dentist; or
(c)	a collaborative prescribing practitioner practising in accordance with the collaborative practice agreement applicable to him.

[S 939/2021 wef 15/12/2021]

Manufacture and supply of drugs in Second Schedule

7.—(1) Despite section 6 of the Act —

(a)	a practitioner or pharmacist, acting in that capacity, may manufacture or compound any drug specified in the Second Schedule; or
(b)	a person lawfully conducting a retail pharmacy business and acting in that capacity may, at the premises at which the person carries on that business, manufacture or compound any drug specified in the Second Schedule.

(2) Despite section 5 of the Act, any of the following persons may, when acting in that capacity, supply or offer to supply any drug specified in the Second Schedule to any person who is permitted by these Regulations to lawfully have that drug in his possession:

(a)	a practitioner;
(b)	a pharmacist;
(c)	a person lawfully conducting a retail pharmacy business;
(d)	a nurse for the time being in charge of a ward, theatre or other department in a hospital when the drug is supplied to the nurse by a person responsible for the dispensing and supply of medicines at that hospital;
(e)	a researcher who is approved by the Director to carry out any scientific research or project approved by the Director that involves any drug specified in the Second Schedule;
(f)	a person who has charge or custody of the controlled drugs in a laboratory approved by the Director for the purpose of carrying out any scientific research or project mentioned in sub-paragraph (e);
(g)	an analyst or any other laboratory staff member employed by the Health Sciences Authority; [S 430/2024 wef 01/06/2024]
(ga)	an analyst or any other laboratory staff member employed by the DSO National Laboratories; [S 796/2025 wef 15/12/2025]
(h)	a collaborative prescribing practitioner practising in accordance with the collaborative practice agreement applicable to him;
(i)	an inspector.

(3) Paragraph (2) does not authorise a nurse for the time being in charge of a ward, theatre or other department in a hospital to supply any drug, except to administer the drug to a patient in that ward, theatre or department (as the case may be) in that hospital in accordance with the directions of any of the following persons:

(a)	a medical practitioner;
(b)	a dentist;
(c)	a collaborative prescribing practitioner practising in accordance with the collaborative practice agreement applicable to him.

(4) Despite section 5 of the Act, the master of a ship which does not carry a medical practitioner on board as part of the ship’s complement may supply or offer to supply any drug specified in the Second Schedule —

(a)	to any member of the crew; or
(b)	to any person who may lawfully supply that drug.

[S 939/2021 wef 15/12/2021]

Manufacture and supply of drugs in Third Schedule

8.—(1) Despite section 6 of the Act —

(a)	a practitioner or pharmacist, acting in that capacity, may manufacture or compound any drug specified in the Third Schedule; or
(b)	a person lawfully conducting a retail pharmacy business and acting in that capacity may, at the premises at which he carries on that business, manufacture or compound any drug specified in the Third Schedule.

[S 939/2021 wef 15/12/2021]

(2) Despite section 5 of the Act, any of the following persons may, when acting in that capacity, supply or offer to supply any drug specified in the Third Schedule to any person who is permitted by these Regulations to lawfully have that drug in his possession:

(a)	a practitioner;
(b)	a pharmacist;
(c)	a person lawfully conducting a retail pharmacy business;
(d)	a nurse for the time being in charge of a ward, theatre or other department in a hospital when the drug is supplied to the nurse by a person responsible for the dispensing and supply of medicines at that hospital;
(e)	a researcher who is approved by the Director to carry out any scientific research or project approved by the Director that involves any drug specified in the Third Schedule;
(f)	a person who has charge or custody of the controlled drugs in a laboratory approved by the Director for the purpose of carrying out any scientific research or project mentioned in sub-paragraph (e);
(g)	an analyst or any other laboratory staff member employed by the Health Sciences Authority; [S 430/2024 wef 01/06/2024]
(ga)	an analyst or any other laboratory staff member employed by the DSO National Laboratories; [S 796/2025 wef 15/12/2025]
(h)	a collaborative prescribing practitioner practising in accordance with the collaborative practice agreement applicable to him;
(i)	an inspector.

[S 939/2021 wef 15/12/2021]

(a)	a medical practitioner;
(b)	a dentist;
(c)	a collaborative prescribing practitioner practising in accordance with the collaborative practice agreement applicable to him.

[S 939/2021 wef 15/12/2021]

(a)	to any member of the crew; or
(b)	to any person who may lawfully supply that drug.

[S 939/2021 wef 15/12/2021]

Supply of drugs in Fourth Schedule

8A. Despite section 5 of the Act, any of the following persons may, when acting in that capacity, supply or offer to supply any drug specified in the Fourth Schedule to any person who is permitted by these Regulations to lawfully have that drug in his possession:

(a)	a researcher who is approved by the Director to carry out any scientific research or project approved by the Director that involves any drug specified in the Fourth Schedule;
(b)	a person who has charge or custody of the controlled drugs in a laboratory approved by the Director for the purpose of carrying out any scientific research or project mentioned in sub-paragraph (a);
(c)	an analyst or any other laboratory staff member employed by the Health Sciences Authority; [S 430/2024 wef 01/06/2024]
(ca)	an analyst or any other laboratory staff member employed by the DSO National Laboratories; [S 796/2025 wef 15/12/2025]
(d)	an inspector.

[S 939/2021 wef 15/12/2021]

Possession of drugs in Second, Third and Fourth Schedules

9.—(1) Despite section 8 of the Act —

(a)	a person specified in regulation 7(2) is permitted to lawfully have any drug specified in the Second Schedule in his possession;
(b)	a person specified in regulation 8(2) is permitted to lawfully have any drug specified in the Third Schedule in his possession; or
(c)	a person specified in regulation 8A is permitted to lawfully have any drug specified in the Fourth Schedule in his possession,

for the purpose of acting in his capacity as such.

(2) Despite section 8 of the Act, a person is permitted to lawfully have any drug specified in the Second or Third Schedule in his possession for administration for medical, dental or veterinary purposes in accordance with the directions of —

(a)	a practitioner; or
(b)	a collaborative prescribing practitioner practising in accordance with the collaborative practice agreement applicable to him.

(3) Paragraph (2) does not apply to a person to whom any controlled drug has been supplied by or on the prescription of a medical practitioner or collaborative prescribing practitioner if —

(a)

that person —

(i)	was then being supplied with any controlled drug by or on the prescription of another medical practitioner or collaborative prescribing practitioner; and
(ii)	had failed to disclose that he had already been supplied with any controlled drug from the firstmentioned medical practitioner or collaborative prescribing practitioner; or

(b)

that person or any other person on his behalf had made a declaration or statement, which was false in any particular, for the purpose of obtaining the supply or prescription.

(4) Despite section 8 of the Act —

(a)	the master of a ship which does not carry a medical practitioner on board as part of the ship’s complement, may have in his possession any drug specified in the Second or Third Schedule so far as necessary for the purpose of compliance with the Merchant Shipping Act; and
(b)	the master of a foreign ship which is in port may have in his possession any drug specified in the Second or Third Schedule so far as necessary for the equipment of the ship.

[S 939/2021 wef 15/12/2021]

PART III

REQUIREMENTS AS TO DOCUMENTATION AND RECORD KEEPING

Documents to be obtained by supplier of controlled drugs

10.—(1) Where a person (referred to in this paragraph as the supplier), not being a practitioner, supplies a controlled drug otherwise than on a prescription, the supplier shall not deliver the drug to a person who —

(a)	purports to be sent by or on behalf of the person to whom it is supplied (referred to in this paragraph as the recipient); and
(b)	is not authorised by any of these Regulations other than regulation 5(1)(d) to have that drug in his possession, [S 939/2021 wef 15/12/2021]

unless that person produces to the supplier a statement in writing signed by the recipient to the effect that he is empowered by the recipient to receive that drug on behalf of the recipient, and the supplier is reasonably satisfied that the document is a genuine document.

(2) Where a person (referred to in this paragraph as the supplier) supplies a controlled drug, otherwise than on a prescription or by way of administration, to any of the persons specified in paragraph (5), the supplier shall not deliver the drug —

(a)

until he has obtained a requisition in writing which —

(i)	is signed by the person to whom the drug is supplied (referred to in this paragraph as the recipient);
(ii)	states the name, address and profession or occupation of the recipient; and
(iii)	specifies the purpose for which the drug supplied is required and the total quantity to be supplied; and

(b)

unless he is reasonably satisfied that the signature is that of the person purporting to have signed the requisition and that that person is engaged in the profession or occupation specified in the requisition.

(3) Where the recipient is a practitioner and he represents that he urgently requires a controlled drug for the purpose of his profession, the supplier may, if he is reasonably satisfied that the recipient so requires the drug and is by reason of some emergency, unable before delivery to furnish to the supplier a requisition in writing duly signed, deliver the drug to the recipient on an undertaking by the recipient to furnish such a requisition within the 24 hours next following.

(4) A person who has given such an undertaking shall deliver to the person by whom the controlled drug was supplied a signed requisition in accordance with the undertaking.

(5) The persons referred to in paragraph (2) are —

(a)	a practitioner or a pharmacist;
(b)	a researcher who is approved by the Director to carry out any scientific research or project approved by the Director that involves any controlled drug; [S 939/2021 wef 15/12/2021]
(c)	a person who has charge or custody of the controlled drugs in a laboratory approved by the Director for the purpose of carrying out any scientific research or project mentioned in sub-paragraph (b); [S 939/2021 wef 15/12/2021]
(d)	the master of a ship which does not carry a medical practitioner on board as part of the ship’s complement; and [S 939/2021 wef 15/12/2021]
(e)	the master of a foreign ship in port. [S 939/2021 wef 15/12/2021]

(6) Where the person responsible for the dispensing and supply of medicines at any hospital supplies a controlled drug to —

(a)	a collaborative prescribing practitioner practising in accordance with the collaborative practice agreement applicable to him in that hospital; or
(b)	the nurse for the time being in charge of any ward, theatre or other department in that hospital,

the person so responsible must —

(c)	obtain a requisition in writing, signed by the collaborative prescribing practitioner or nurse (as the case may be), which specifies the total quantity of the drug to be supplied; and
(d)	mark the requisition in such manner as to show that it has been complied with.

[S 939/2021 wef 15/12/2021]

(7) Any requisition obtained for the purposes of paragraph (6) shall be retained in the dispensary from which the drug was supplied and a copy of the requisition or a note of it shall be retained or kept by the recipient.

(8) Nothing in this regulation shall have effect in relation to the drugs specified in the First Schedule.

Form of prescriptions

11.—(1) Subject to this regulation, a person shall not issue a prescription containing a controlled drug other than a drug specified in the First Schedule unless the prescription complies with the following requirements:

The prescription shall —

(a)

be in ink or otherwise so as to be indelible and be signed by the person issuing it with his usual signature and dated by him;

(b)

insofar as it specifies the information required by sub‑paragraphs (d), (f) and (g), be written by the person issuing it in his own handwriting;

(c)

have written thereon, if issued by a dentist, the words “for dental treatment only” and, if issued by a veterinary surgeon, the words “for animal treatment only”;

(d)

specify the name and address of the person for whose treatment it is issued or, if it is issued by a veterinary surgeon, of the person to whom the controlled drug prescribed is to be delivered;

(e)

specify the name and address of the person issuing the prescription;

(f)

specify the dose to be taken and —

(i)	in the case of a prescription containing a controlled drug which is a preparation, the form and, where appropriate, the strength of the preparation, and either the total quantity (in both words and figures) of the preparation or the number (in both words and figures) of dosage units, as appropriate, to be supplied; and
(ii)	in any other case, the total quantity (in both words and figures) of the controlled drug to be supplied; and

(g)

in the case of a prescription for a total quantity intended to be dispensed by instalments, contain a direction specifying the amount of the instalments of the total amount which may be dispensed and the intervals to be observed when dispensing.

(2) In the case of a prescription issued for the treatment of a patient in a hospital, it shall be a sufficient compliance with paragraph (1)(d) if the prescription is written on the patient’s bed card or case sheet.

Provisions as to supply on prescription

12.—(1) A person shall not supply a controlled drug other than a drug specified in the First Schedule on a prescription before the date specified in the prescription and later than 30 days after the date specified in the prescription and —

(a)	unless the prescription complies with regulation 11;
(b)	unless the address specified in the prescription as the address of the person issuing it, is an address within Singapore; and
(c)	unless he either is acquainted with the signature of the person by whom it purports to be issued and has no reason to suppose that it is not genuine, or has taken reasonably sufficient steps to satisfy himself that it is genuine.

(2) A person dispensing a prescription containing a controlled drug other than a drug specified in the First Schedule shall —

(a)	at the time of dispensing it, mark thereon the date on which it is dispensed; and
(b)	retain the prescription on the premises on which it was dispensed.

Marking of bottles and other containers

13.—(1) Subject to paragraph (2), no person shall supply a controlled drug otherwise than in a bottle, package or other container which is plainly marked —

(a)

in the case of a controlled drug other than a preparation, with the amount of the drug contained therein; and

(b)

in the case of a controlled drug which is a preparation —

(i)	made up into tablets, capsules or other dosage units, with the amount of each component (being a controlled drug) of the preparation in each dosage unit and the number of dosage units in the bottle, package or other container; or
(ii)	not made up as mentioned in sub-paragraph (i), with the total amount of the preparation in the bottle, package or other container and the percentage of each of its components which is a controlled drug.

(2) Nothing in this regulation shall have effect in relation to the drugs specified in the First Schedule or in relation to the supply of a controlled drug by or on the prescription of a practitioner.

Keeping of registers

14.—(1) Every person authorised by or under these Regulations to supply any drug specified in the Second or Fourth Schedule shall comply with the following requirements:

(a)

he shall, in accordance with this regulation and regulation 15, keep a register and shall enter therein in chronological sequence in the form specified in Part I or II of the Fifth Schedule, as the case may require, particulars of every quantity of a drug specified in the Second or Fourth Schedule obtained by him and of every quantity of such a drug supplied (whether by way of administration or otherwise) by him whether to persons within or outside Singapore, except that the register if kept in a ward, theatre or other department in a hospital (other than the dispensary within the hospital) shall be in the form specified in the Sixth Schedule instead of the Fifth Schedule; and

(b)

he shall use a separate register or separate part of the register for entries made in respect of each class of drugs, and each of the drugs specified in paragraphs 1, 3 and 6 of the Second Schedule and paragraphs 1 and 3 of the Fourth Schedule together with its salts and any preparation or other product containing it or any of its salts shall be treated as a separate class, so however that any stereoisomeric form of a drug or its salts shall be classed with that drug.

(2) Nothing in paragraph (1) shall be taken as preventing the use of a separate section within a register or separate part of a register in respect of different drugs or strengths of drugs comprised within the class of drugs to which that register or separate part relates.

Requirement as to registers

15. Any person required to keep a register under regulation 14 shall comply with the following requirements:

(a)

the class of drugs to which the entries on any page of any such register relate shall be specified at the head of that page;

(b)

every entry required to be made under regulation 14 in such a register shall be made on the day on which the drug is obtained or, as the case may be, on which the transaction in respect of the supply of the drug by the person required to make the entry takes place or, if that is not reasonably practicable, on the day next following that day;

(c)

no cancellation, obliteration or alteration of any such entry shall be made, and a correction of such an entry shall be made only by way of marginal note or footnote which shall specify the date on which the correction is made;

(d)

every such entry and every correction of such an entry shall be made in ink or otherwise so as to be indelible;

(e)

such a register shall not be used for any purpose other than for the purposes of these Regulations;

(f)

the person so required to keep such a register shall on demand made by any person authorised in writing by the Minister in that behalf —

(i)	furnish such particulars as may be requested in respect of the obtaining or supplying by him of any drug specified in the Second or Fourth Schedule or in respect of any stock of the drugs in his possession;
(ii)	for the purpose of confirming any such particulars, produce any stock of the drugs in his possession; and
(iii)	produce the register and such other books or documents in his possession relating to any dealings in drugs specified in the Second or Fourth Schedule as may be requested;

(g)

a separate register shall be kept in respect of each premises at which the person required to keep the register carries on his business or occupation, but subject to that not more than one register shall be kept at one time in respect of each class of drugs in respect of which he is required to keep a separate register, so, however, that a separate register may, with the approval of the Minister, be kept in respect of each department of the business carried on by him; and

(h)

every such register in which entries are currently being made shall be kept at the premises to which it relates.

Record keeping requirements in case of ship

16. Where a drug specified in the Second Schedule is supplied in accordance with regulation 7(4) to a member of the crew of a ship, an entry in the official log book required to be kept under the Merchant Shipping Act (Cap. 179) or, in the case of a ship which is not required to carry such an official log book, a report signed by the master of the ship shall, notwithstanding anything in these Regulations, be a sufficient record of the supply if the entry or report specifies the drug supplied.

Preservation of registers, books and other documents

17.—(1) All registers and books kept under regulation 14 or 16 shall be preserved for a period of 3 years from the date on which the last entry is made.

(2) Every requisition, order or prescription, on which a controlled drug is supplied under these Regulations, shall be preserved for a period of 3 years from the date on which the last delivery under it was made.

Preservation of records relating to drugs in First Schedule

18.—(1) A manufacturer of any drug specified in the First Schedule and a wholesale dealer in any such drug shall keep every invoice or other like record issued in respect of each quantity of that drug obtained by him and in respect of each quantity of the drug supplied by him.

(2) A retail dealer in any drug specified in the First Schedule shall keep every invoice or other like record issued in respect of each quantity of that drug obtained by him.

(3) Every document kept in pursuance of this regulation shall be preserved for a period of 3 years from the date on which it is issued.

(4) The keeping of a copy of the document made at any time during the period of 3 years shall be treated for the purposes of this regulation as if it were the keeping of the original document.

PART IV

MISCELLANEOUS

Treatment of drug addicts

19. A medical practitioner who attends to a person whom he considers or has reasonable grounds to suspect is a drug addict shall, within 7 days from the date of attendance, furnish to both the Director of Medical Services and the Director of the Central Narcotics Bureau the following information relating to that person, through such means as may be specified by the Director of the Central Narcotics Bureau:

(a)

name;

(b)

identity card number;

(c)

sex;

(d)

age;

(e)

address;

(f)

the drug to which the person is believed to be addicted; and

(g)

the grounds on which the medical practitioner considers or has reasonable grounds to suspect that the person is a drug addict, which may include —

(i)	the frequency and dates the medical practitioner, or any other medical practitioner working in the same hospital as him, has attended to the person;
(ii)	the physical symptoms of the person; and
(iii)	the amount and types of prescriptions requested by, or provided to, the person at the hospital in which the medical practitioner works. [S 525/2010 wef 20/09/2010]

Storage of controlled drugs

20.—(1) All stocks of controlled drugs (except those specified in the First Schedule) must be kept in a safe, cabinet or room that is constructed for the storage of the controlled drugs and maintained to prevent unauthorised access to the controlled drugs —

(a)	where the controlled drugs are for use in a ward, theatre or department of a hospital — in the hospital premises under the control of the nurse in charge of that ward, theatre or department; or
(b)	in any other case — in the dispensary or any other premises under the control of a pharmacist or the person authorised to supply controlled drugs under these Regulations.

(2) The safe, cabinet or room mentioned in paragraph (1) must be locked using at least one of the following:

(a)	a physical lock and key;
(b)	an electronic access control system;
(c)	a biometric access control system.

(3) The nurse, pharmacist or authorised person mentioned in paragraph (1) —

(a)

where the safe, cabinet or room (as the case may be) is locked using a physical lock and key — must keep the key in his or her personal possession at all times;

(b)

where the safe, cabinet or room (as the case may be) is locked using an electronic access control system —

(i)	must keep the access card in his or her personal possession at all times; and
(ii)	must not disclose the access code (if any) to any other person; and

(c)

where the safe, cabinet or room (as the case may be) is locked using a biometric access control system — must ensure that only his or her particulars are enabled for the purpose of unlocking the biometric access control system.

(4) Any person who fails to comply with the requirements of this regulation shall be guilty of an offence and shall be liable on conviction to a fine not exceeding $2,000.

[S 796/2025 wef 15/12/2025]

Appointment of inspectors

21.—(1) The Minister may appoint such persons as he thinks fit by name or office to be inspectors for the purposes of these Regulations.

(2) An inspector may —

(a)	at all reasonable times enter upon any premises in which he reasonably believes controlled drugs are kept or stored; and
(b)	with such assistance as he considers necessary, inspect stocks of controlled drugs held in the premises, take abstracts of and take possession of records and documents relating to purchases, sales and supply of controlled drugs from the premises.

Inspector may purchase sample

22.—(1) An inspector may purchase any article advertised for sale or offered or exposed for sale, which he knows or has reason to believe to consist of or contain any controlled drug.

(2) The person in possession or charge of the article mentioned in paragraph (1) shall supply that article to the inspector and shall not charge more than the advertised or a reasonable price therefor.

(3) An inspector making any such purchase may —

(a)	select the actual case, bottle or package which he requires; or
(b)	demand to be served from any receptacle pointed out by him,

and the person in possession or charge shall comply with such requirement or demand.

(4) An inspector purchasing any article with the intention of submitting that article to analysis shall immediately on completion of the purchase —

(a)	notify the seller or his agent selling the article his intention to have the article analysed;
(b)	divide the article into 3 parts;
(c)	mark and seal or fasten up each one of the parts in such manner as its nature will permit;
(d)	deliver one of the parts to the seller or his agent and another to the Health Sciences Authority for analysis; and [S 140/2001 wef 01/04/2001]
(e)	retain the third part for comparison.

(5) Any person who, without any reasonable excuse, contravenes paragraph (1), (2) or (3) shall be guilty of an offence and shall be liable on conviction to a fine not exceeding $2,000.

Inspection of weights and measures

23.—(1) Any inspector may, at all reasonable times, inspect all weights, measures and instruments for weighing used by or in the possession of any person for use for weighing a controlled drug.

(2) Any person who on demand made by an inspector —

(a)	neglects or refuses to produce for inspection any such weights, measures or instruments for weighing used by him or in his possession or on his premises; or
(b)	refuses to permit the inspector to examine or remove for examination the weights, measures or instruments,

shall be guilty of an offence and shall be liable on conviction to a fine not exceeding $500, and in the case of a second or subsequent offence, to a fine not exceeding $1,000.

Penalties for supplying false information

24.—(1) Any person who wilfully supplies false information as to any particulars required to be entered in any register under these Regulations shall be guilty of an offence and shall be liable on conviction to a fine not exceeding $10,000 or to imprisonment for a term not exceeding 2 years or to both.

(2) Any person who enters in any register required to be kept under these Regulations false information as to any particulars prescribed to be entered knowing the same to be false or not believing it to be true shall be guilty of an offence and shall be liable on conviction to a fine not exceeding $10,000 or to imprisonment for a term not exceeding 2 years or to both.

Making false document

25. Any person who —

(a)	makes a false document for the purpose of obtaining any controlled drug from any authorised person; or
(b)	uses as genuine such a false document knowing or having reason to believe it to be false,

shall be guilty of an offence and shall be liable on conviction to a fine not exceeding $10,000 or to imprisonment for a term not exceeding 2 years or to both.

False declaration or statement

26. Any person who —

(a)	for the purpose of obtaining, whether for himself or for any other person, the issue, grant or renewal of any licence under these Regulations, makes any declaration or statement which is false in any material particular; or
(b)	knowingly utters, produces, or makes use of any such declaration or statement or any document containing the declaration or statement,

shall be guilty of an offence and shall be liable on conviction to a fine not exceeding $10,000 or to imprisonment for a term not exceeding 2 years or to both.

General penalty

27. Any person who contravenes or fails to comply with any of the provisions of these Regulations shall be guilty of an offence and, if no specific penalty has been provided for the offence, shall be liable on conviction to a fine not exceeding $5,000 or to imprisonment for a term not exceeding 12 months or to both.

Destruction of controlled drugs

28.—(1) No person who is required by any provision of, or by any term or condition of a licence having effect under, these Regulations to keep records with respect to a drug specified in the Second or Fourth Schedule shall destroy such a drug or cause the drug to be destroyed except in the presence of and in accordance with any directions given by an inspector or such other person as the Minister may authorise.

(2) Where a drug is destroyed under paragraph (1) by or at the instance of a person who is required by any provision of, or by any term or condition of a licence having effect under, these Regulations to keep a record in respect of the obtaining or supply of that drug, that record shall —

(a)	include particulars of the date of destruction and the quantity destroyed; and
(b)	be signed by the inspector or authorised person in whose presence the drug is destroyed.

(3) Where the master of a ship has in his possession a drug specified in the Second and Third Schedules which he no longer requires, he shall not destroy the drug or cause it to be destroyed but shall dispose of it to an inspector.

Withdrawal of authorisation

29. Where a practitioner or a pharmacist —

(a)	has been convicted of an offence under the Act or under these Regulations; or
(b)	has been prescribing, administering or supplying a controlled drug in a manner which appears to the Minister to be irresponsible,

the Minister may, by order, direct that the practitioner or pharmacist shall cease to have any authority under Part II to manufacture, possess, prescribe, administer or supply controlled drugs and the order shall have effect notwithstanding anything to the contrary in these Regulations.

FIRST SCHEDULE

Regulations 3, 10, 11, 12, 13, 18 and 20

CONTROLLED DRUGS EXCEPTED FROM SECTIONS 5, 6, 7 AND 8 OF ACT AND SUBJECT TO REQUIREMENTS OF REGULATION 18

1.—(1) Any preparation of one or more of the substances to which this paragraph applies, not being a preparation designed for administration by injection, when compounded with one or more other active or inert ingredients and containing a total of not more than 100 milligrams of the substance or substances (calculated as base) per dosage unit with a total concentration of not more than 2.5% (calculated as base) in undivided preparations.

(2) The substances to which this paragraph applies are acetyldihydrocodeine, codeine, dihydrocodeine, ethylmorphine, nicocodine, nicodicodine (6‑nicotinoyldi-hydrocodeine), norcodeine, pholcodine and their respective salts.

[S 439/2022 wef 01/06/2022]

2. Any preparation of cocaine containing not more than 0.1% of cocaine calculated as cocaine base, being a preparation compounded with one or more other active or inert ingredients in such a way that the cocaine cannot be recovered by readily applicable means or in a yield which would constitute a risk to health.

3. Any preparation of medicinal opium or of morphine containing (in either case) not more than 0.2% of morphine calculated as anhydrous morphine base, being a preparation compounded with one or more other active or inert ingredients in such a way that the opium or, as the case may be, the morphine, cannot be recovered by readily applicable means or in a yield which would constitute a risk to health.

4. Preparations of dextropropoxyphene for oral use containing not more than 135 milligrams of dextropropoxyphene base per dosage unit and with a concentration of not more than 2.5% in undivided preparations.

5. Preparations of difenoxin containing, per dosage unit, not more than 0.5 milligram of difenoxin and a quantity of atropine sulphate equivalent to at least 5% of the dosage of difenoxin.

6. Any preparation of diphenoxylate containing, per dosage unit, not more than 2.5 milligrams of diphenoxylate calculated as base, and a quantity of atropine sulphate equivalent to at least 1% of the dose of diphenoxylate.

7. Any preparation of propiram containing, per dosage unit, not more than 100 milligrams of propiram calculated as base and compounded with at least the same amount of methylcellulose in weight.

8. Any powder of ipecacuanha and opium comprising —

(a)	10% opium, in powder; and
(b)	10% ipecacuanha root, in powder,

well mixed with 80% of any other powdered ingredient containing no controlled drug.

9. Any mixture containing one or more of the preparations specified in paragraphs 1 to 7, being a mixture of which none of the other ingredients is a controlled drug.

[S 939/2021 wef 15/12/2021]

[G.N. Nos. S 234/73; S 47/74; S 60/75; S 186/76; S 13/78; S 89/79; S 177/81; S 358/82; S 237/83; S 228/84; S 337/84; S 30/86; S 209/86; S 49/90; S 565/91; S 65/92; S 278/92; S 491/93; S 222/96; S 389/97]

SECOND SCHEDULE

Regulations 6, 7, 9, 14, 15, 16 and 28

Controlled Drugs Subject to Requirements of Regulations 10, 11, 12, 13, 14, 15, 16 and 28

1. The following substances and products, namely:

Acetorphine

Acetylmethadol (also known as methadyl acetate)

Allylprodine

Alphacetylmethadol

Alphameprodine

Alphamethadol

Alphaprodine

Anileridine

Benzethidine

Benzylmorphine (3-benzylmorphine)

Betacetylmethadol

Betameprodine

Betamethadol

Betaprodine

Bezitramide

Buprenorphine

Clonitazene

Cocaine

Codoxime

Desomorphine

Dextromoramide

(2S)-2,6-Diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide (also known as Lisdexamphetamine or Lisdexamfetamine) and its stereoisomers

Diamorphine

Diampromide

Diethylthiambutene

Difenoxin

Dihydroetorphine

Dihydromorphine

Dimenoxadole

Dimepheptanol

Dimethylthiambutene

Dioxaphetyl butyrate

Diphenoxylate

Dipipanone

Drotebanol

Ecgonine, and any derivative of ecgonine which is convertible to ecgonine or to cocaine

Ethylmethylthiambutene

Ethylphenidate

Etonitazene

Etorphine

Etoxeridine

Furethidine

Gamma hydroxybutyric acid

Hydrocodone

Hydromorphinol

Hydromorphone

Hydroxypethidine

Isomethadone

Ketamine and its acyloxy or sulphonyl derivatives at the nitrogen atom, and the following example of such a derivative:

(1)	tert-Butyl N-methyl-N-((2-chlorophenyl)-1-oxocyclohexan-2-yl)carbamate (also known as N-tert-Butoxycarbonyl-ketamine or t-Boc-ketamine)

Ketobemidone

Levomethorphan

Levomoramide

Levophenacylmorphan

Levorphanol

Medicinal opium

Metazocine

Methadone

[Deleted by S 283/2021 wef 01/05/2021]

Methyldesorphine

Methyldihydromorphine (6-methyldihydromorphine)

Metopon

monoacetylmorphine

Morpheridine

Morphine

Morphine methobromide, morphine N-oxide and other pentavalent nitrogen morphine derivatives

Myrophine

Nicomorphine

Noracymethadol

norbuprenorphine

norketamine and its dehydro derivatives

Norlevorphanol

Normethadone

Normorphine

Norpipanone

Oxycodone

Oxymorphone

parahexyl (3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl 6H-dibenzo [b,d] pyran)

Pethidine

Phenadoxone

Phenampromide

Phenazocine

Phenomorphan

Phenoperidine

Piminodine

Piritramide

Proheptazine

Properidine

Racemethorphan

Racemoramide

Racemorphan

[Deleted by S 234/2018 wef 01/05/2018]

Tapentadol

Thebacon

Thebaine

Tilidine

Trimeperidine

[Deleted by S 506/2005 wef 01/08/2005]

[Deleted by S 193/2017 wef 01/05/2017]

4-Cyano-2-dimethylamino-4, 4-diphenylbutane

4-Cyano-1-methyl-4-phenylpiperidine

2-(Diethylamino)-1-phenyl-1-propanone (also known as amfepramone or diethylpropion or diethylcathinone)

[Deleted by S 199/2016 wef 01/05/2016]

1-Methyl-4-phenylpiperidine-4-carboxylic acid

2-Methyl-3-morpholino-1, 1-diphenylpropanecarboxylic acid

4-methylthioamphetamine

[Deleted by S 234/2018 wef 01/05/2018]

4-Phenylpiperidine-4-carboxylic acid ethyl ester

6,7,8,14-Tetradehydro-4,5-α-epoxy-6-methoxy-17-methylmorphinan-3-ol (also known as 3-O-demethylthebaine or Oripavine).

[S 283/2021 wef 01/05/2021]

[S 750/2020 wef 04/09/2020]

[S 390/99 wef 09/09/1999]

[S 231/2000 wef 15/05/2000]

[S 490/2006 wef 14/08/2006]

[S 270/2013 wef 01/05/2013]

[S 571/2014 wef 01/09/2014]

[S 199/2016 wef 01/05/2016]

[S 193/2017 wef 01/05/2017]

[S 234/2018 wef 01/05/2018]

[S 353/2019 wef 01/05/2019]

2. Any stereoisomeric form of a substance specified in paragraph 1, not being dextromethorphan or dextrorphan.

3. Any ester or ether of a substance specified in paragraph 1 or 2, not being a substance specified in paragraph 6.

4. Any salt of a substance specified in paragraph 1, 2 or 3.

5. Any preparation or other product containing a substance or product specified in paragraph 1, 2, 3 or 4, not being a preparation specified in the First Schedule.

6. The following substances and product, namely:

Acetyldihydrocodeine

Amphetamine

Codeine

Dextropropoxyphene

Dihydrocodeine

Ethylmorphine (3-ethylmorphine)

Etomidate (with effect from 1 September 2025 to 30 April 2026, both dates inclusive)

Fenetylline

Flunitrazepam

Mecloqualone

Methaqualone

Methamphetamine (also known as Methylamphetamine) and its acyloxy or sulphonyl derivatives at the nitrogen atom, and the following examples of such a derivative:

(1)	tert-Butyl N-methyl-N-(1-phenylpropan-2-yl)carbamate (also known as N-tert-Butoxycarbonyl-methamphetamine or t-Boc-methamphetamine)

(2)	N,4-Dimethyl-N-(3-phenyl-propan-2-yl)benzenesulfonamide (also known as N-Tosyl-methamphetamine)

Methylphenidate

Metomidate (with effect from 1 September 2025 to 30 April 2026, both dates inclusive)

Nicocodine

Nicodicodine (6-nicotinoyldidro-codeine)

Nimetazepam

Norcodeine

Phencyclidine

Phenmetrazine

Pholcodine

Propiram

Secobarbital

Triazolam

Zipeprol.

[S 77/2026 wef 28/02/2026]

[S 557/2025 wef 01/09/2025]

[S 750/2020 wef 04/09/2020]

7. Any stereoisomeric form of a substance specified in paragraph 6.

8. Any salt of a substance specified in paragraph 6 or 7.

9. Any preparation or other product containing a substance or product specified in paragraph 6, 7 or 8, not being a preparation specified in the First Schedule.

10. Fentanyl and any compounds structurally derived from N‑(1‑Methyl‑4‑piperidyl)‑N‑phenyl formamide by substitution of any of the hydrogen atoms, including any salt of any substance falling within this item:

(1)	Acetylfentanyl (also known as desmethyl fentanyl)
(1A)	Acryloylfentanyl (also known as Acrylfentanyl) [S 234/2018 wef 01/05/2018]
(2)	Alfentanil
(3)	Alpha‑methyl fentanyl
(4)	Alpha‑methyl fentanyl acetanilide
(5)	Alpha‑methylthiofentanyl
(6)	Benzyl fentanyl
(7)	Beta‑hydroxy fentanyl
(8)	Beta‑hydroxy‑3‑methyl fentanyl
(8A)	Butyryl fentanyl (also known as butyrfentanyl) [S 193/2017 wef 01/05/2017]
(9)	Carfentanil
(9AAA)	Crotonylfentanyl [S 350/2020 wef 01/05/2020]
(9AA)	Cyclopropylfentanyl [S 353/2019 wef 01/05/2019]
(9AB)	4-Fluorobutyrfentanyl (also known as para-Fluoro-butyrfentanyl or p-Fluoro-butyrfentanyl) [S 353/2019 wef 01/05/2019]
(9AC)	2-Fluorofentanyl (also known as ortho-Fluorofentanyl) [S 353/2019 wef 01/05/2019]
(9AD)	3-Fluorofentanyl (also known as meta-Fluorofentanyl) [S 353/2019 wef 01/05/2019]
(9AE)	4-Fluorofentanyl (also known as para-Fluorofentanyl) [S 353/2019 wef 01/05/2019]
(9A)	4-Fluoroisobutyrfentanyl (also known as 4-FIBF or pFIBF) [S 234/2018 wef 01/05/2018]
(9B)	Furanyl fentanyl [S 234/2018 wef 01/05/2018]
(10)	Lofentanil
(10A)	Methoxyacetylfentanyl [S 353/2019 wef 01/05/2019]
(10B)	4-Methoxybutyrfentanyl (also known as para-Methoxy-butyrfentanyl or p-Methoxy-butyrylfentanyl) [S 353/2019 wef 01/05/2019]
(11)	3‑Methyl fentanyl
(11A)	3-Methylthiofentanyl [S 234/2018 wef 01/05/2018]
(11B)	Ocfentanil [S 234/2018 wef 01/05/2018]
(12)	[Deleted by S 353/2019 wef 01/05/2019]
(12A)	Remifentanil [S 234/2018 wef 01/05/2018]
(13)	Sufentanil
(13A)	Tetrahydrofuranyl fentanyl (also known as THF-F) [S 234/2018 wef 01/05/2018]
(14)	Thiafentanil
(15)	Thiofentanyl [S 199/2016 wef 01/05/2016]
(16)	Valerylfentanyl [S 350/2020 wef 01/05/2020]

THIRD SCHEDULE

Regulations 6, 8, 9 and 28

Controlled Drugs Subject to Requirements of Regulations 10, 11, 12 and 13

1. The following substances, namely:

Benzphetamine

Chlorphentermine

Mephentermine

Phendimetrazine

Pipradrol.

2. Any stereoisomeric form of a substance specified in paragraph 1.

3. Any salt of a substance specified in paragraph 1 or 2.

4. Any preparation or other product containing a substance specified in paragraph 1, 2 or 3, not being a preparation specified in the First Schedule.

FOURTH SCHEDULE

Regulations 8A, 9, 14, 15 and 28

Controlled Drugs Subject to Requirements of Regulations 10, 11, 12, 13, 14, 15 and 28

1. The following substances and products, namely:

(1)

1-Benzylpiperazine (also known as BZP)

(2)

1-(4-Bromo-2,5-dimethoxyphenyl)propan-2-amine (also known as 4-Bromo-2,5-dimethoxy-α-methylphenethylamine, 4-Bromo-2,5-dimethoxyamphetamine, Brolamfetamine or DOB) and its bromo and dimethoxy positional isomers in the phenyl ring

[S 350/2020 wef 01/05/2020]

(3)

2-(4-Bromo-2,5-dimethoxyphenyl)ethanamine (also known as 4-bromo-2,5-dimethoxyphenethylamine or 2C-B) and its bromo and dimethoxy positional isomers in the phenyl ring

[S 193/2017 wef 01/05/2017]

(4)

[Deleted by S 199/2016 wef 01/05/2016]

(5)

Cannabinol

(6)

Cannabinol derivatives as defined in Part 4 of the First Schedule to the Act

[S 454/2023 wef 01/07/2023]

(7)

Cannabis and cannabis resin

(8)

Cathinone

(9)

Coca leaf

(10)

Concentrate of poppy-straw

(11)

N,N-Diethyl-3-hydroxy-7-methyl-2-oxo-4,6,6a,7,8,9-hexahydroindolo-[4,3-fg]quinoline-9-carboxamide (also known as 2-Oxo-3-hydroxy-LSD) and its acyclic secondary and tertiary amide structural isomers

[S 791/2019 wef 01/12/2019]

(12)

1-(2,5-Dimethoxy-4-methylphenyl)propan-2-amine (also known as 2,5-Dimethoxy-4,α-dimethylphenethylamine, 2-Amino-1-(2,5-dimethoxy-4-methyl)phenylpropane or DOM) and its methyl and dimethoxy positional isomers in the phenyl ring

[S 350/2020 wef 01/05/2020]

(13)

2,5-Dimethoxy-α-methylphenethylamine (also known as 2,5-Dimethoxyamphetamine or DMA) and its dimethoxy positional isomers in the phenyl ring

[S 791/2019 wef 01/12/2019]

(14)

N,α-Dimethyl-3,4-(methylenedioxy)phenethylamine (also known as 3,4-Methylenedioxymethamphetamine or MDMA) and its acyloxy or sulphonyl derivatives at the nitrogen atom, and the following example of such a derivative:

(a)	tert-Butyl N-[1-(1,3-benzodioxol-5-yl)propan-2-yl]-N-methylcarbamate (also known as N-tert-Butoxycarbonyl-MDMA or t-Boc-MDMA) [S 750/2020 wef 04/09/2020]

(15)

3-(1,2-Dimethylhepty1)-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran (also known as DMHP)

[S 791/2019 wef 01/12/2019]

(16)

[Deleted by S 199/2016 wef 01/05/2016]

(17)

4-Ethyl-2,5-dimethoxy-α-methylphenethylamine (also known as DOET)

[S 791/2019 wef 01/12/2019]

(18)

N-Ethyl-α-methyl-3,4-(methylenedioxy)phenethylamine (also known as MDEA)

(19)

Eticyclidine

(20)

[Deleted by S 199/2016 wef 01/05/2016]

(21)

1-Hydroxy-3-pentyl-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6-H-dibenzo[b,d]pyran

(22)

Lysergamide

(23)

Lysergide and other compounds structurally derived from lysergamide by substitution of any of the hydrogen atoms, and the following examples of such a compound:

(a)	1-Acetyl-N,N-diethyllysergamide (also known as N-acetyl-LSD or ALD-52)
(b)	6-Allyl-6-nor-lysergic acid diethylamide (also known as N-allyl-nor-LSD or AL-LAD)
(c)	6-Ethyl-6-nor-lysergic acid diethylamide (also known as ETH-LAD)
(d)	6-Propyl-6-nor-lysergic acid diethylamide (also known as PRO-LAD)
(e)	Lysergic acid 2,4-dimethylazetidide (also known as LSZ)
(f)	1-Propionyl-N,N-diethyllysergamide (also known as 1-Propionyl-LSD or 1P-LSD)
(g)	1-Butanoyl-N,N-diethyllysergamide (also known as 1-Butanoyl-LSD or 1B-LSD)
(h)	1-Cyclopropionyl-N,N-diethyllysergamide (also known as 1-Cyclopropionyl-LSD or 1cP-LSD) [S 283/2021 wef 01/05/2021] [S 750/2020 wef 04/09/2020]

(24)

Mescaline

(25)

3-Methoxy-α-methyl-4,5-(methylenedioxy)phenethylamine (also known as 5-methoxy-MDA or MMDA)

[S 791/2019 wef 01/12/2019]

(26)

p-Methoxy-α-methylphenethylamine (also known as 4-methoxyamphetamine or para-methoxyamphetamine) and its methoxy positional isomers in the phenyl ring

[S 193/2017 wef 01/05/2017]

(27)

N-Methyl-α-ethyl-3,4-(methylenedioxy)phenethylamine (also known as MBDB)

(28)

N-[α-Methyl-3,4-(methylenedioxy)phenethyl]hydroxylamine (also known as N-Hydroxy MDA)

[S 791/2019 wef 01/12/2019]

(29)

α-Methyl-3,4-(methylenedioxy)phenethylamine (also known as Tenamfetamine or MDA)

(30)

4-Methylaminorex

(31)

4-Phenyl-N-(2-phenylethyl)piperidin-4-yl acetate (also known as 1-Phenethyl-4-phenyl-4-piperidinol acetate or PEPAP)

[S 353/2019 wef 01/05/2019]

(32)

Psilocybine

(33)

Rolicyclidine

(34)

Tenocyclidine

(35)

1-(3-Trifluoromethylphenyl)piperazine (also known as TFMPP)

(36)

[Deleted by S 283/2021 wef 01/05/2021]

2. Opium, not being medicinal opium or a preparation falling within paragraph 3 or 8 of the First Schedule.

3. Any stereoisomeric form of a substance specified in paragraph 1.

4. Any ester or ether of a substance specified in paragraph 1 or 3.

5. Any salt of a substance specified in paragraph 1, 3 or 4.

6. Any preparation or other product containing a substance or product specified in paragraph 1, 3, 4 or 5, not being a preparation specified in the First Schedule.

7. [Deleted by S 750/2020 wef 04/09/2020]

8. Any compound containing a 3-(1-naphthylmethyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, and any derivatives of the above compounds containing hydroxy and/or carboxylic acid groups, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including any salt or stereoisomeric form of the above compounds or derivatives, and any preparation or product containing the above compounds or derivatives, for example:

(1)	3-[(4-Methylnaphthalen-1-yl)methyl]-1-pentyl-1H-indole (also known as JWH-184)
(2)	3-(Naphthalen-1-ylmethyl)-1-pentyl-1H-indole (also known as JWH-175) [S 322/2014 wef 01/05/2014]

9. Any compound containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, and any derivatives of the above compounds containing hydroxy and/or carboxylic acid groups, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including any salt or stereoisomeric form of the above compounds or derivatives, and any preparation or product containing the above compounds or derivatives, for example:

(1)	[5-(2-Chlorophenyl)-1-pentyl-1H-pyrrol-3-yl](naphthalen-1-yl)methanone (also known as JWH-369)
(2)	[5-(2-Fluorophenyl)-1-pentyl-1H-pyrrol-3-yl](naphthalen-1-yl)methanone (also known as JWH-307)
(3)	[5-(3-Fluorophenyl)-1-pentyl-1H-pyrrol-3-yl](naphthalen-1-yl)methanone (also known as JWH-368)
(4)	(1-Hexyl-5-phenyl-1H-pyrrol-3-yl)(naphthalen-1-yl)methanone (also known as JWH-147)
(5)	(1-Hexyl-1H-pyrrol-3-yl)(naphthalen-1-yl)methanone (also known as JWH-031)
(6)	[5-(2-Methylphenyl)-1-pentyl-1H-pyrrol-3-yl](naphthalen-1-yl)methanone (also known as JWH-370)
(7)	Naphthalen-1-yl[5-(naphthalen-1-yl)-1-pentyl-1H-pyrrol-3-yl]methanone (also known as JWH-309)
(8)	Naphthalen-1-yl(1-pentyl-5-phenyl-1H-pyrrol-3-yl)methanone (also known as JWH-145)
(9)	Naphthalen-1-yl(1-pentyl-1H-pyrrol-3-yl)methanone (also known as JWH-030) [S 322/2014 wef 01/05/2014]

10. Any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, and any derivatives of the above compounds containing hydroxy and/or carboxylic acid groups, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including any salt or stereoisomeric form of the above compounds or derivatives, and any preparation or product containing the above compounds or derivatives, for example:

(1)	E-1-[1-(1-Naphthalenylmethylene)-1H-inden-3-yl]pentane (also known as JWH-176) [S 322/2014 wef 01/05/2014]

11. [Deleted by S 750/2020 wef 04/09/2020]

12. Any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, and any derivatives of the above compounds containing hydroxy and/or carboxylic acid groups, whether or not substituted in the cyclohexyl ring to any extent, including any salt or stereoisomeric form of the above compounds or derivatives, and any preparation or product containing the above compounds or derivatives, for example:

(1)	2-[5-Hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol (also known as CP55,940)
(2)	2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2-yl)phenol (also known as CP47,497) [S 322/2014 wef 01/05/2014]

13. [Deleted by S 750/2020 wef 04/09/2020]

14. [Deleted by S 750/2020 wef 04/09/2020]

15. Any compound, other than bupropion and 2-(Diethylamino)-1-phenyl-1-propanone (also known as amfepramone or diethylpropion or diethylcathinone), that is structurally derived from 2-amino-1-phenylpropan-1-one by modification in any of the following ways:

(a)	substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl, or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents;
(b)	substitution at the 3-position with an alkyl substituent;
(c)	substitution at the nitrogen atom with alkyl, cycloalkyl or dialkyl, benzyl or methoxybenzyl groups, or by inclusion of the nitrogen atom in a cyclic structure, [S 454/2023 wef 01/07/2023]

including any salt or stereoisomeric form of the above compounds, and any preparation or product containing the above compounds, for example:

(1)	1-(1,3-Benzodioxol-5-yl)-2-(benzylamino)propan-1-one (also known as 3,4-Methylenedioxy-N-benzylcathinone or BMDP) [S 193/2017 wef 01/05/2017]
(1AAAA)	1-(1,3-Benzodioxol-5-yl)-2-(butylamino)butan-1-one (also known as N-butylbutylone) [S 472/2025 wef 01/07/2025]
(1AAA)	1-(1,3-Benzodioxol-5-yl)-2-(cyclohexylamino)propan-1-one (also known as 3,4-methylenedioxy-N-cyclohexylcathinone or 3,4-methylenedioxy-α-cyclohexylaminopropiophenone or N-cyclohexylmethylone or Cyputylone) [S 454/2023 wef 01/07/2023]
(1AA)	1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)-1-butanone (also known as Dibutylone or bk-DMBDB) [S 234/2018 wef 01/05/2018]
(1A)	1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)-1-propanone (also known as bk-MDDMA) [S 193/2017 wef 01/05/2017]
(1ABA)	1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)pentan-1-one (also known as N,N-dimethylpentylone, dipentylone or bk-DMBDP) [S 454/2023 wef 01/07/2023]
(1AB)	1-(1,3-Benzodioxol-5-yl)-2-(ethylamino)-1-butanone (also known as Eutylone) [S 234/2018 wef 01/05/2018]
(1AC)	1-(1,3-Benzodioxol-5-yl)-2-(ethylamino)pentan-1-one (also known as 1-(2H-1,3-Benzodioxol-5-yl)-2-(ethylamino)pentan-1-one) or N-Ethylpentylone or N-Ethylnorpentylone or Ephylone) [S 234/2018 wef 01/05/2018] [S 353/2019 wef 01/05/2019]
(1B)	1-(1,3-Benzodioxol-5-yl)-2-(ethylamino)propan-1-one (also known as ethylone or 3,4-Methylenedioxy-N-ethylcathinone or bk-MDEA or MDEC) [S 193/2017 wef 01/05/2017]
(2)	1-(1,3-Benzodioxol-5-yl)-2-(isopropylamino)butan-1-one (also known as N-isopropylbutylone or NiPB) [S 472/2025 wef 01/07/2025]
(3)	1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one (also known as butylone)
(4)	1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one (also known as pentylone)
(5)	1-(1,3-Benzodioxol-5-yl)-2-(methylamino)propan-1-one (also known as methylone or 3,4-methylenedioxy-N-methylcathinone)
(6)	1-(1,3-Benzodioxol-5-yl)-2-(pyrrolidin-1-yl)butan-1-one (also known as MDPBP)
(6A)	1-(1,3-Benzodioxol-5-yl)-2-(pyrrolidin-1-yl)hexan-1-one (also known as 3,4-Methylenedioxy-α-pyrrolidinohexanophenone or 3,4-MDPHP) [S 439/2022 wef 01/06/2022]
(7)	1-(1,3-Benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one (also known as 3,4-methylenedioxypyrovalerone or MDPV)
(8)	1-(1,3-Benzodioxol-5-yl)-2-(pyrrolidin-1-yl)propan-1-one (also known as MDPPP)
(8A)	2-(Benzylamino)-1-(4-methylphenyl)propan-1-one (also known as Benzedrone); [S 193/2017 wef 01/05/2017]
(8AAA)	1-(4-Bromophenyl)-2-(ethylamino)propan-1-one (also known as 4-Bromoethcathinone or 4-BEC) [S 234/2018 wef 01/05/2018]
(8AA)	1-(4-Bromophenyl)-2-(methylamino)propan-1-one (also known as 4-Bromomethcathinone or Brephedrone or 4-BMC) [S 193/2017 wef 01/05/2017]
(8AAAA)	2-(Butylamino)-1-phenylhexan-1-one (also known as N-Butylhexedrone or α-Butylaminohexanophenone) [S 439/2022 wef 01/06/2022]
(8AAB)	1-(4-Chlorophenyl)-2-(dimethylamino)propan-1-one (also known as 4-Chloro-N,N-dimethylcathinone) [S 791/2019 wef 01/12/2019]
(8AB)	1-(4-Chlorophenyl)-2-(ethylamino)propan-1-one (also known as 4-Chloroethcathinone or 4-CEC) [S 234/2018 wef 01/05/2018]
(8AC)	1-(3-Chlorophenyl)-2-(methylamino)propan-1-one (also known as 3-chloromethcathinone or 3-CMC) [S 430/2024 wef 01/06/2024]
(8B)	1-(4-Chlorophenyl)-2-(methylamino)propan-1-one (also known as 4-Chloromethcathinone or Clephedrone or 4-CMC) [S 253/2015 wef 01/05/2015]
(9)	2-(Dimethylamino)-1-phenylpropan-1-one (also known as metamfepramone or dimethylcathinone)
(10)	1-(3,4-Dimethylphenyl)-2-(methylamino)propan-1-one (also known as 3,4-Dimethylmethcathinone or 3,4-DMMC) [S 253/2015 wef 01/05/2015]
(10A)	2-(Ethylamino)-1-(4-ethylphenyl)propan-1-one (also known as 4-Ethylethcathinone) [S 193/2017 wef 01/05/2017]
(10B)	2-(Ethylamino)-1-(4-fluorophenyl)propan-1-one (also known as 4-Fluoroethcathinone or 4-FEC) [S 193/2017 wef 01/05/2017]
(10C)	2-(Ethylamino)-1-(4-methylphenyl)pentan-1-one (also known as 4-Methyl-α-ethylaminopentiophenone or 4-MEAPP) [S 234/2018 wef 01/05/2018]
(11)	2-(Ethylamino)-1-(4-methylphenyl)propan-1-one (also known as 4-Methylethcathinone or 4-MEC) [S 253/2015 wef 01/05/2015]
(12)	2-(Ethylamino)-1-phenylbutan-1-one (also known as N-ethylbuphedrone)
(12A)	2-(Ethylamino)-1-phenylhexan-1-one (also known as N-Ethylhexedrone or Ethyl-hexedrone) [S 350/2020 wef 01/05/2020]
(13)	2-(Ethylamino)-1-phenylpentan-1-one (also known as α-Ethylaminopentiophenone or N-Ethylpentedrone) [S 791/2019 wef 01/12/2019]
(14)	2-(Ethylamino)-1-phenylpropan-1-one (also known as ethcathinone)
(14A)	1-(4-Ethylphenyl)-2-(methylamino)propan-1-one (also known as 4-Ethylmethcathinone or 4-EMC) [S 253/2015 wef 01/05/2015]
(14B)	1-(4-Fluoro-3-methylphenyl)-2-(pyrrolidin-1-yl)pentan-1-one (also known as 4-Fluoro-3-methyl-α-pyrrolidinopentiophenone or 4-Fluoro-3-methyl-α-PVP) [S 283/2021 wef 01/05/2021]
(15)	1-(4-Fluorophenyl)-2-(methylamino)propan-1-one (also known as 4-Fluoromethcathinone or Flephedrone or 4-FMC) [S 253/2015 wef 01/05/2015]
(15AA)	1-(4-Fluorophenyl)-2-(pyrrolidin-1-yl)hexan-1-one (also known as 4-Fluoro-PHP) [S 234/2018 wef 01/05/2018]
(15A)	1-(4-Fluorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one (also known as 4-Fluoro-α-PVP) [S 253/2015 wef 01/05/2015]
(16)	1-(4-Methoxyphenyl)-2-(methylamino)propan-1-one (also known as 4-Methoxymethcathinone or Methedrone or bk-PMMA or PMMC) [S 253/2015 wef 01/05/2015]
(17)	1-(4-Methoxyphenyl)-2-(pyrrolidin-1-yl)propan-1-one (also known as MOPPP)
(17A)	2-(Methylamino)-1-(4-methylphenyl)butan-1-one (also known as 4-Methylbuphedrone or 4-Me-MABP) [S 193/2017 wef 01/05/2017]
(18)	2-(Methylamino)-1-phenylbutan-1-one (also known as buphedrone)
(19)	2-(Methylamino)-1-phenylpentan-1-one (also known as pentedrone or α-Methylaminovalerophenone) [S 193/2017 wef 01/05/2017]
(20)	2-(Methylamino)-1-phenylpropan-1-one (also known as methcathinone)
(20A)	4-Methyl-1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one (also known as α-PiHP or α-pyrrolidinoisohexanophenone) [S 454/2023 wef 01/07/2023]
(21)	1-(4-Methylphenyl)-2-(methylamino)propan-1-one (also known as 4-Methylmethcathinone or Mephedrone or 4-MMC) [S 253/2015 wef 01/05/2015]
(21A)	1-(3-Methylphenyl)-2-(methylamino)propan-1-one (also known as 3-methylmethcathinone, metaphedrone or 3-MMC) [S 454/2023 wef 01/07/2023]
(22)	1-(4-Methylphenyl)-2-(pyrrolidin-1-yl)butan-1-one (also known as MPBP)
(22A)	1-(4-Methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one (also known as 4-Methyl-α-pyrrolidinohexanophenone or MPHP) [S 193/2017 wef 01/05/2017]
(23)	1-(4-Methylphenyl)-2-(pyrrolidin-1-yl)pentan-1-one (also known as pyrovalerone)
(23A)	1-(4-Methylphenyl)-2-(pyrrolidin-1-yl)propan-1-one (also known as 4-Methyl-α-pyrrolidinopropiophenone or 4-MePPP) [S 193/2017 wef 01/05/2017]
(24)	1-Phenyl-2-(pyrrolidin-1-yl)butan-1-one (also known as α-PBP)
(24A)	1-Phenyl-2-(pyrrolidin-1-yl)hexan-1-one (also known as Alpha-Pyrrolidinohexiophenone or Alpha-PHP or α-PHP) [S 350/2020 wef 01/05/2020]
(25)	1-Phenyl-2-(pyrrolidin-1-yl)pentan-1-one (also known as α-PVP)
(26)	1-Phenyl-2-(pyrrolidin-1-yl)propan-1-one (also known as α-PPP) [S 322/2014 wef 01/05/2014] [S 193/2017 wef 01/05/2017]

16. Any compound that is structurally derived from 2-aminopropan-1-one by substitution at the 1-position with any monocyclic, or fused-polycyclic ring system (not being a phenyl ring or alkylenedioxyphenyl ring system), whether or not the compound is further modified in any of the following ways:

(a)	substitution in the ring system to any extent with alkyl, alkoxy, haloalkyl, or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents;
(b)	substitution at the 3-position with an alkyl substituent;
(c)	substitution at the 2-amino nitrogen atom with alkyl, cycloalkyl or dialkyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure, [S 454/2023 wef 01/07/2023]

including any salt or stereoisomeric form of the above compounds, and any preparation or product containing the above compounds, for example:

(1)	1-(Naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (also known as naphyrone or naphthylpyrovalerone)
(2)	2-(Pyrrolidin-1-yl)-1-(thiophen-2-yl)pentan-1-one (also known as α-Pyrrolidinopentiothiophenone or α-PVT) [S 322/2014 wef 01/05/2014]

17. The following compounds, including any salt or stereoisomeric form of such compounds, and any preparation or product containing such compounds:

(1)	[Deleted by S 750/2020 wef 04/09/2020]
(1AAA)	[Deleted by S 791/2019 wef 01/12/2019]
(1A)	[Deleted by S 750/2020 wef 04/09/2020]
(1AA)	[Deleted by S 750/2020 wef 04/09/2020]
(1AB)	[Deleted by S 750/2020 wef 04/09/2020]
(1AC)	[Deleted by S 750/2020 wef 04/09/2020]
(1AD)	[Deleted by S 750/2020 wef 04/09/2020]
(1AE)	[Deleted by S 750/2020 wef 04/09/2020]
(1AF)	[Deleted by S 750/2020 wef 04/09/2020]
(1AG)	[Deleted by S 750/2020 wef 04/09/2020]
(1B)	[Deleted by S 750/2020 wef 04/09/2020]
(2)	[Deleted by S 750/2020 wef 04/09/2020]
(2AAA)	[Deleted by S 750/2020 wef 04/09/2020]
(2A)	2‑Amino‑1‑(4‑bromo‑2,5‑dimethoxyphenyl)ethan‑1‑one (also known as bk‑2C‑B) and its bromo and dimethoxy positional isomers in the phenyl ring [S 199/2016 wef 01/05/2016]
(2AA)	N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-indazole-3-carboxamide (also known as ADB-INACA or ADMB-INACA) and its N-(1-amino-1-oxohexan-2-yl) isomers [S 430/2024 wef 01/06/2024]
(2B)	N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-5-bromo-1H-indazole-3-carboxamide (also known as ADB-5-Bromo-INACA) and its N-(1-amino-1-oxohexan-2-yl) isomers and their respective bromo positional isomers in the 6-membered ring of the indazole structure [S 439/2022 wef 01/06/2022] [S 454/2023 wef 01/07/2023]
(2AAB)	[Deleted by S 750/2020 wef 04/09/2020]
(2AB)	[Deleted by S 750/2020 wef 04/09/2020]
(2BA)	[Deleted by S 750/2020 wef 04/09/2020]
(2C)	[Deleted by S 750/2020 wef 04/09/2020]
(2CA)	[Deleted by S 750/2020 wef 04/09/2020]
(2CB)	[Deleted by S 750/2020 wef 04/09/2020]
(2D)	[Deleted by S 750/2020 wef 04/09/2020]
(2DA)	[Deleted by S 750/2020 wef 04/09/2020]
(2DB)	[Deleted by S 750/2020 wef 04/09/2020]
(2E)	[Deleted by S 750/2020 wef 04/09/2020]
(2F)	[Deleted by S 750/2020 wef 04/09/2020]
(2G)	[Deleted by S 750/2020 wef 04/09/2020]
(2GA)	[Deleted by S 750/2020 wef 04/09/2020]
(2H)	[Deleted by S 750/2020 wef 04/09/2020]
(2I)	[Deleted by S 750/2020 wef 04/09/2020]
(2IA)	[Deleted by S 750/2020 wef 04/09/2020]
(2J)	[Deleted by S 750/2020 wef 04/09/2020]
(2K)	[Deleted by S 750/2020 wef 04/09/2020]
(2L)	4‑(2‑Aminopropyl)benzofuran (also known as 4‑APB) [S 199/2016 wef 01/05/2016]
(3)	5-(2-Aminopropyl)benzofuran (also known as 5-APB)
(4)	6-(2-Aminopropyl)benzofuran (also known as 6-APB or BenzoFury)
(4A)	7-(2-Aminopropyl)benzofuran (also known as 7-APB) [S 253/2015 wef 01/05/2015]
(4B)	4-(2-Aminopropyl)-2,3-dihydrobenzofuran (also known as 4-APDB) [S 253/2015 wef 01/05/2015]
(5)	5-(2-Aminopropyl)-2,3-dihydrobenzofuran (also known as 5-APDB)
(6)	6-(2-Aminopropyl)-2,3-dihydrobenzofuran (also known as 6-APDB)
(6A)	7-(2-Aminopropyl)-2,3-dihydrobenzofuran (also known as 7-APDB) [S 253/2015 wef 01/05/2015]
(6AA)	1‑(1‑Benzofuran‑5‑yl)‑N‑ethylpropan‑2‑amine (also known as 5‑EAPB) and its 4‑yl, 6‑yl and 7‑yl isomers [S 199/2016 wef 01/05/2016]
(6B)	1-Benzyl-4-methylpiperazine (also known as Methylbenzylpiperazine or MBZP) [S 234/2018 wef 01/05/2018]
(6C)	2-Bis(4-fluorophenyl)methylsulfinyl-N-methylacetamide (also known as N-Methyl-4,4-difluoromodafinil or modafiendz) and its fluoro positional isomers in the phenyl rings [S 234/2018 wef 01/05/2018]
(6D)	2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (also known as 25B-NBOMe) and its bromo, dimethoxy and methoxy positional isomers in the respective phenyl rings [S 234/2018 wef 01/05/2018]
(6E)	2-N-[2-(4-Bromo-2,5-dimethoxyphenylethyl)aminomethyl]phenol (also known as 25B-NBOH) and its bromo, dimethoxy and hydroxy positional isomers in the respective phenyl rings [S 234/2018 wef 01/05/2018]
(6F)	4-Bromo-N-[2-(dimethylamino)cyclohexyl]-benzamide (also known as Bromadoline or U-47931E) and its bromo positional isomers in the phenyl ring and diamino positional isomers in the cyclohexyl ring [S 283/2021 wef 01/05/2021]
(6G)	4-Bromo-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzamide (also known as N-Methyl U-47931E or N-Methyl Bromadoline) and its bromo positional isomers in the phenyl ring and diamino positional isomers in the cyclohexyl ring [S 283/2021 wef 01/05/2021]
(6H)	1-(1-(1-(4-Bromophenyl)ethyl)-piperidin-4-yl)-1,3-dihydro-2H-benzimidazol-2-one (also known as Brorphine) and its bromo positional isomers in the phenyl ring [S 430/2024 wef 01/06/2024]
(6I)	2-(2-(4-Butoxybenzyl)-5-nitro-1H-benzo[d]imidazol-1-yl)-N,N-diethylethan-1-amine (also known as butonitazene or butoxynitazene) and its diethylamino and butoxy structural isomers and their respective butoxy positional isomers in the phenyl ring and nitro positional isomers in the 6-membered ring of the benzimidazole structure [S 454/2023 wef 01/07/2023]
(7)	17-Carboxy-16,17-dihydromitragynine
(8)	16-Carboxymitragynine
(8A)	2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (also known as 2C-C) and its chloro and dimethoxy positional isomers in the phenyl ring [S 234/2018 wef 01/05/2018]
(8AAA)	1-(4-Chloro-2,5-dimethoxyphenyl)propan-2-amine (also known as 4-Chloro-2,5-dimethoxy-α-methylphenethylamine, 4-Chloro-2,5-dimethoxyamphetamine, DOC, 3C-C, 4-Cl-2,5-DMA or 4-Chloro-2,5-DMA) and its chloro and dimethoxy positional isomers in the phenyl ring [S 350/2020 wef 01/05/2020]
(8AA)	2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (also known as 25C-NBOMe) and its chloro, dimethoxy and methoxy positional isomers in the respective phenyl rings [S 234/2018 wef 01/05/2018]
(8AB)	2-N-[2-(4-Chloro-2,5-dimethoxyphenylethyl)aminomethyl]phenol (also known as 25C-NBOH) and its chloro, dimethoxy and hydroxy positional isomers in the respective phenyl rings [S 234/2018 wef 01/05/2018]
(8AC)	5-(Cyclobutylmethyl)-2-(2-phenylpropan-2-yl)-pyrido[4,3-b]indol-1-one (also known as Cumyl-CB-MeGACLONE, Cumyl-CBMGACLONE, cumyl-cyclobutylmethyl-gammacarbolinone or SGT-273) and its phenylpropyl isomers [S 454/2023 wef 01/07/2023]
(8AD)	[Deleted by S 750/2020 wef 04/09/2020]
(8B)	1‑Cyclohexyl‑4‑(1,2‑diphenylethyl)piperazine (also known as MT‑45) [S 199/2016 wef 01/05/2016]
(8BA)	N-Cyclohexyl-2-(1-(4-hydroxypentyl)-1H-indol-3-yl)acetamide and its hydroxy positional isomers in the pentyl group [S 454/2023 wef 01/07/2023]
(8BB)	N-Cyclohexyl-2-(1-pentyl-1H-indol-3-yl)acetamide (also known as CH-PIATA) [S 454/2023 wef 01/07/2023]
(8C)	2-(1-(Cyclohexylmethyl)-2-oxo-1,2-dihydro-3H-indol-3-ylidene)benzohydrazide (also known as N’-(1-(Cyclohexylmethyl)-2-oxoindolin-3-ylidene)benzohydrazide or BZO-CHMOXIZID) [S 439/2022 wef 01/06/2022]
(9)	17-O-Desmethyl-16,17-dihydromitragynine
(10)	9-O-Desmethylmitragynine
(10AAA)	3,4-Dibromo-N-methyl-N-(1-methyl-1-azaspiro[4.5]decan-6-yl)benzamide (also known as U-77891) and its dibromo positional isomers in the phenyl ring and their respective azaspiro[4.5]decanyl isomers [S 283/2021 wef 01/05/2021]
(10AA)	3,4-Dichloromethylphenidate and its dichloro positional isomers in the phenyl ring (also known as 3,4-DCMP) [S 353/2019 wef 01/05/2019]
(10A)	3,4-Dichloro-N-{[1-(dimethylamino)cyclohexyl]methyl}benzamide (also known as AH-7921) and its dichloro positional isomers in the phenyl ring [S 253/2015 wef 01/05/2015]
(10B)	3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide (also known as U-47700) and its dichloro positional isomers in the phenyl ring and diamino positional isomers in the cyclohexyl ring [S 193/2017 wef 01/05/2017]
(10C)	N,N-Diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benzo[d]imidazol-1-yl)ethan-1-amine (also known as Isotonitazene) and its diethylamino structural isomers and their respective isopropoxy positional isomers in the phenyl ring and nitro positional isomers in the 6-membered ring of the benzimidazole structure [S 283/2021 wef 01/05/2021]
(10D)	N,N-Diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1H-benzo[d]imidazol-1-yl)ethan-1-amine (also known as Metonitazene) and its diethylamino structural isomers and their respective methoxy positional isomers in the phenyl ring and nitro positional isomers in the 6-membered ring of the benzimidazole structure [S 439/2022 wef 01/06/2022]
(10E)	N,N-Diethyl-2-(2-(4-propoxybenzyl)-5-nitro-1H-benzo[d]imidazol-1-yl)ethan-1-amine (also known as protonitazene or propoxynitazene) and its diethylamino structural isomers and their respective propoxy positional isomers in the phenyl ring and nitro positional isomers in the 6-membered ring of the benzimidazole structure [S 454/2023 wef 01/07/2023]
(11)	2,3-Dihydro-1H-inden-2-amine (also known as 2-Aminoindane)
(12)	6,7-Dihydro-5H-indeno[5,6-d][1,3]dioxol-6-amine (also known as 5,6-(methylenedioxy)-2-aminoindane or MDAI)
(13)	2,3-Dihydro-5-iodo-1H-inden-2-amine (also known as 5-Iodo-2-aminoindane or 5-IAI)
(14)	[2,3-Dihydro-5-methyl-3-(morpholin-4-ylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl](naphthalen-1-yl)methanone
(14A)	[Deleted by S 750/2020 wef 04/09/2020]
(15)	{4-[2,6-Dimethoxy-4-(2-methyloctan-2-yl)phenyl]-6,6-dimethyl-bicyclo[3.1.1]hept-2-en-2-yl}methanol
(15A)	2-(2,5-Dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (also known as 25H-NBOMe) and its dimethoxy and methoxy positional isomers in the respective phenyl rings [S 234/2018 wef 01/05/2018]
(15B)	2‑(2,5‑Dimethoxyphenyl)ethanamine (also known as 2C‑H) and its dimethoxy positional isomers in the phenyl ring [S 199/2016 wef 01/05/2016]
(15C)	2-N-[2-(2,5-Dimethoxyphenylethyl)aminomethyl]phenol (also known as 25H-NBOH) and its dimethoxy and hydroxy positional isomers in the respective phenyl rings [S 234/2018 wef 01/05/2018]
(16)	6,6-Dimethyl-3-(2-methyloctan-2-yl)-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-1,9-diol
(17)	N,N-Dimethyl-1-phenylpropan-2-amine (also known as N,N-dimethylamphetamine)
(18)	Diphenyl(pyrrolidin-2-yl)methanol (also known as diphenylprolinol)
(18A)	1-(1,2-Diphenylethyl)piperidine (also known as Diphenidine) [S 283/2021 wef 01/05/2021]
(19)	2-Diphenylmethylpiperidine (also known as desoxypipradrol)
(19AAA)	2-(2-(4-Ethoxybenzyl)-1H-benzo[d]imidazol-1-yl)-N,N-diethylethan-1-amine (also known as etodesnitazene, etazene, etazen, etazone or desnitroetonitazene) and its diethylamino structural isomers and their respective ethoxy positional isomers in the phenyl ring [S 454/2023 wef 01/07/2023]
(19AAAAA)	2-(4-Ethoxybenzyl)-5-nitro-1-(2-piperidin-1-ylethyl)-1H-benzo[d]imidazole (also known as etonitazepipne or N-piperidinyl etonitazene) and its ethoxy positional isomers in the phenyl ring and their respective nitro positional isomers in the 6-membered ring of the benzimidazole structure [S 472/2025 wef 01/07/2025]
(19AAB)	2-(4-Ethoxybenzyl)-5-nitro-1-(2-pyrrolidin-1-ylethyl)-1H-benzimidazole (also known as etonitazepyne or N-pyrrolidino etonitazene) and its ethoxy positional isomers in the phenyl ring and their respective nitro positional isomers in the 6-membered ring of the benzimidazole structure [S 454/2023 wef 01/07/2023]
(19AA)	N-Ethyl-1-(3-fluorophenyl)propan-2-amine (also known as 3-Fluoroethamphetamine, 3-Fluoroethylamphetamine or 3-FEA) and its fluoro positional isomers in the phenyl ring [S 439/2022 wef 01/06/2022]
(19AAAA)	N-Ethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benzo[d]imidazol-1-yl)ethan-1-amine (also known as norisotonitazene or N-desethyl isotonitazene) and its ethylamino and isopropoxy structural isomers and their respective isopropoxy positional isomers in the phenyl ring and nitro positional isomers in the 6-membered ring of the benzimidazole structure [S 472/2025 wef 01/07/2025]
(19AB)	N-Ethyl-1-(3-methoxyphenyl)-cyclohexanamine (also known as 3-Methoxyeticyclidine or 3-Methoxy-PCE or 3-MeO-PCE) and its methoxy positional isomers in the phenyl ring [S 430/2024 wef 01/06/2024]
(19AC)	2-(Ethylamino)-2-(2-fluorophenyl)-cyclohexanone (also known as 2-fluorodeschloro-N-ethyl-ketamine, 2-FDCNEK, 2-fluoro-2-oxo PCE or 2-fluoro NENDCK) and its fluoro positional isomers in the phenyl ring [S 430/2024 wef 01/06/2024]
(19A)	2-(Ethylamino)-2-phenyl-cyclohexan-1-one (also known as Deschloro-N-ethyl-ketamine) [S 283/2021 wef 01/05/2021]
(19ABD)	2-(2-(1-(4-Fluorobenzyl)-1H-(6-hydroxyindol)-3-yl)acetamido)-3,3-dimethylbutanamide and its N-(1-amino-1-oxohexan-2-yl) isomers and their respective fluoro positional isomers in the phenyl ring and hydroxy positional isomers in the 6-membered ring of the indole structure [S 439/2022 wef 01/06/2022]
(19ABE)	2-(2-(1-(4-Fluorobenzyl)-1H-indol-3-yl)acetamido)-3,3-dimethylbutanamide (also known as ADB-FUBIATA or FUB-ACADB or AD-18) and its N-(1-amino-1-oxohexan-2-yl) isomers and their respective fluoro positional isomers in the phenyl ring [S 439/2022 wef 01/06/2022]
(19AAC)	[Deleted by S 750/2020 wef 04/09/2020]
(19ABA)	[Deleted by S 750/2020 wef 04/09/2020]
(19ABB)	[Deleted by S 750/2020 wef 04/09/2020]
(19ABC)	[Deleted by S 750/2020 wef 04/09/2020]
(19ABF)	2-Fluorodeschloroketamine (also known as 2-Fluoroketamine or 2-FDCK) and its fluoro positional isomers in the phenyl ring [S 350/2020 wef 01/05/2020]
(19B)	4-Fluoromethylphenidate and its fluoro positional isomers in the phenyl ring [S 234/2018 wef 01/05/2018] [S 430/2024 wef 01/06/2024] [S 796/2025 wef 15/12/2025]
(19B)	[Deleted by S 750/2020 wef 04/09/2020]
(20A)	[Deleted by S 750/2020 wef 04/09/2020]
(20AA)	[Deleted by S 750/2020 wef 04/09/2020]
(20AB)	5-(5-Fluoropentyl)-2-(2-phenylpropan-2-yl)-pyrido[4,3-b]indol-1-one (also known as 2-Cumyl-5-(5-fluoropentyl)-gamma-carbolin-1-one or 5-Fluoro-cumyl-PEGACLONE) and its phenylpropyl isomers and their respective fluoro positional isomers in the pentyl group [S 350/2020 wef 01/05/2020]
(20)	2-(1-(5-Fluoropentyl)-2-oxo-1,2-dihydro-3H-indol-3-ylidene)benzohydrazide (also known as N’-(1-(5-Fluoropentyl)-2-oxoindolin-3-ylidene)benzohydrazide or 5-Fluoro-BZO-POXIZID or 5F-BZO-POXIZID or MDA-19 5-fluoropentyl analogue or 5F-MDA-19) and its fluoro positional isomers in the pentyl group [S 439/2022 wef 01/06/2022]
(20B)	2-(3-Fluorophenyl)-3-methylmorpholine (also known as 3-Fluorophenmetrazine or 3F-phenmetrazine) and its fluoro positional isomers in the phenyl ring [S 283/2021 wef 01/05/2021]
(20C)	[Deleted by S 750/2020 wef 04/09/2020]
(20D)	[Deleted by S 750/2020 wef 04/09/2020]
(21)	1-(4-Fluorophenyl)piperazine (also known as 4-Fluorophenylpiperazine or 4-FPP) and its fluoro positional isomers in the phenyl ring [S 253/2015 wef 01/05/2015]
(22)	1-(4-Fluorophenyl)propan-2-amine (also known as 4-Fluoroamphetamine or 4-FA) and its fluoro positional isomers in the phenyl ring [S 253/2015 wef 01/05/2015]
(22A)	2-(1-Hexyl-2-oxo-1,2-dihydro-3H-indol-3-ylidene)benzohydrazide (also known as N’-(1-Hexyl-2-oxoindolin-3-ylidene)benzohydrazide or BZO-HEXOXIZID or MDA-19) [S 439/2022 wef 01/06/2022]
(22B)	N’-(1-Hexyl-2-oxoindolin-3-ylidene)-4-hydroxybenzohydrazide and its hydroxy positional isomers in the phenyl ring [S 454/2023 wef 01/07/2023]
(23)	1-Hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6,6a,7,8,10,10a-hexahydro-9H-benzo[c]chromen-9-one
(24)	[9-Hydroxy-6-methyl-3-(5-phenylpentan-2-yl)oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate
(25)	3-Hydroxy-2-[3-methyl-6-(2-propenyl)-cyclohex-2-en-1-yl]-5-pentyl-1,4-benzoquinone
(25AA)	N’-(1-(4-Hydroxycyclohexylmethyl)-2-oxoindolin-3-ylidene)benzohydrazide and its hydroxy positional isomers in the cyclohexyl group [S 454/2023 wef 01/07/2023]
(25A)	2-(1-(5-Hydroxyhexyl)-2-oxo-1,2-dihydro-3H-indol-3-ylidene)benzohydrazide (also known as N’-(1-(5-Hydroxyhexyl)-2-oxoindolin-3-ylidene)benzohydrazide) and its hydroxy positional isomers in the hexyl group [S 439/2022 wef 01/06/2022]
(26)	9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-1-ol (for example HU-210, HU-211) [S 193/2017 wef 01/05/2017]
(27)	7-Hydroxymitragynine
(27AAA)	2-(1-(5-Hydroxypentyl)-2-oxo-1,2-dihydro-3H-indol-3-ylidene)benzohydrazide (also known as N’-(1-(5-Hydroxypentyl)-2-oxoindolin-3-ylidene)benzohydrazide) and its hydroxy positional isomers in the pentyl group [S 439/2022 wef 01/06/2022]
(27AA)	5-(5-Hydroxypentyl)-2-(2-phenylpropan-2-yl)-pyrido[4,3-b]indol-1-one and its phenylpropyl isomers and their respective hydroxy positional isomers in the pentyl group [S 283/2021 wef 01/05/2021]
(27AB)	2-(1H-Indazole-3-carboxamido)-3,3-dimethylbutanoic acid and its hexanoic acid isomers [S 430/2024 wef 01/06/2024]
(27A)	1‑(1H‑Indol‑5‑yl)propan‑2‑amine (also known as 5‑IT) and its 4‑yl, 6‑yl and 7‑yl isomers [S 199/2016 wef 01/05/2016]
(27B)	2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (also known as 25I-NBOMe) and its dimethoxy, iodo and methoxy positional isomers in the respective phenyl rings [S 234/2018 wef 01/05/2018]
(27C)	2‑(4‑Iodo‑2,5‑dimethoxyphenyl)ethanamine (also known as 2C‑I) and its dimethoxy and iodo positional isomers in the phenyl ring [S 199/2016 wef 01/05/2016]
(27D)	2-N-[2-(4-Iodo-2,5-dimethoxyphenylethyl)aminomethyl]phenol (also known as 25I-NBOH) and its dimethoxy, hydroxy and iodo positional isomers in the respective phenyl rings [S 234/2018 wef 01/05/2018]
(27DA)	[Deleted by S 750/2020 wef 04/09/2020]
(27DB)	[Deleted by S 750/2020 wef 04/09/2020]
(27E)	3-Methoxy-2-(methylamino)-1-(4-methylphenyl)propan-1-one (also known as Mexedrone) and its methyl positional isomers in the phenyl ring [S 234/2018 wef 01/05/2018]
(27EA)	2-(4-Methoxybenzyl)-5-nitro-1-(2-pyrrolidin-1-ylethyl)-1H-benzo[d]imidazole (also known as metonitazepyne or N-pyrrolidino metonitazene) and its methoxy positional isomers in the phenyl ring and their respective nitro positional isomers in the 6-membered ring of the benzimidazole structure [S 472/2025 wef 01/07/2025]
(27F)	N-[1-(3-Methoxyphenyl)cyclohexyl]-piperidine (also known as 3-Methoxyphencyclidine or 3-Methoxy-PCP or 3-MeO-PCP) and its methoxy positional isomers in the phenyl ring [S 791/2019 wef 01/12/2019]
(28)	2-(3-Methoxyphenyl)-2-(N-ethylamino)cyclohexanone (also known as methoxetamine)
(28A)	1-[1-(2-Methoxyphenyl)-2-phenylethyl]piperidine (also known as 2-MeO-Diphenidine or 2-MXP or methoxphenidine) and its methoxy positional isomers in the phenyl ring [S 283/2021 wef 01/05/2021]
(28B)	N-Methyl-5-(2-aminopropyl)benzofuran (also known as 5-MAPB) and its 4-yl, 6-yl and 7-yl isomers [S 283/2021 wef 01/05/2021]
(28BA)	[Deleted by S 750/2020 wef 04/09/2020]
(28C)	[Deleted by S 750/2020 wef 04/09/2020]
(28CA)	[Deleted by S 750/2020 wef 04/09/2020]
(28D)	[Deleted by S 750/2020 wef 04/09/2020]
(28E)	[Deleted by S 750/2020 wef 04/09/2020]
(28F)	[Deleted by S 750/2020 wef 04/09/2020]
(28FA)	[Deleted by S 750/2020 wef 04/09/2020]
(28G)	[Deleted by S 750/2020 wef 04/09/2020]
(28H)	[Deleted by S 750/2020 wef 04/09/2020]
(28I)	[Deleted by S 750/2020 wef 04/09/2020]
(28J)	[Deleted by S 750/2020 wef 04/09/2020]
(29)	N-Methyl-1-(4-fluorophenyl)propan-2-amine (also known as 4-Fluoromethamphetamine or 4-FMA) and its fluoro positional isomers in the phenyl ring [S 253/2015 wef 01/05/2015]
(29A)	Methyl 2-(1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (also known as MDMB-INACA) and its hexanoate isomers [S 472/2025 wef 01/07/2025]
(29B)	2-(5-Methyl-1H-indazole-3-carboxamido)-3,3-dimethylbutanoic acid and its hexanoic acid isomers and their respective methyl positional isomers in the 6-membered ring of the indazole structure [S 472/2025 wef 01/07/2025]
(29AA)	[Deleted by S 750/2020 wef 04/09/2020]
(30)	N-Methyl-1-(4-methoxyphenyl)propan-2-amine (also known as 4-Methoxymethamphetamine or para-Methoxymethamphetamine or PMMA) and its methoxy positional isomers in the phenyl ring [S 253/2015 wef 01/05/2015]
(30AA)	Methyl 2-(5-methyl-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (also known as MDMB-5-Methyl-INACA or MDMB-5-Me-INACA) and its hexanoate isomers and their respective methyl positional isomers in the 6-membered ring of the indazole structure [S 472/2025 wef 01/07/2025]
(30A)	4‑Methyl‑5‑(4‑methylphenyl)‑4,5‑dihydro‑1,3‑oxazol-2‑amine (also known as 4,4’‑Dimethylaminorex, 4,4’‑DMAR or para‑methyl‑4‑methylaminorex) and its methyl positional isomers in the phenyl ring [S 199/2016 wef 01/05/2016]
(31)	N-Methyl-1-(4-methylphenyl)propan-2-amine (also known as 4-Methylmethamphetamine or 4-MMA) and its methyl positional isomers in the phenyl ring [S 253/2015 wef 01/05/2015]
(31A)	1-(2-Methyl-4-(3-phenyl-prop-2-en-1-yl)-piperazin-1-yl)-1-butanone (also known as 2-methyl-AP-237 or 2-methyl buccinazine) and its methyl positional isomers in the piperazinyl ring [S 454/2023 wef 01/07/2023]
(32)	(N-Methyl-4-phenylpiperidin-4-yl)propanoate (also known as 1-Methyl-4-phenyl-4-piperidinol propionate, desmethylprodine or MPPP) [S 588/2018 wef 01/10/2018]
(33)	N‑Methyl‑1‑(thiophen‑2‑yl)propan‑2‑amine (also known as methiopropamine) and its thiophen‑3‑yl isomer [S 199/2016 wef 01/05/2016]
(34)	1-(4-Methylbenzo-1,3-dioxol-6-yl)propan-2-amine (also known as 5-methyl-MDA or 5-methyl-3,4-methylenedioxyamphetamine)
(35)	Mitragynine
(35A)	[Deleted by S 750/2020 wef 04/09/2020]
(36)	Naphthalen-1-yl(4-pentyloxynaphthalen-1-yl)methanone (also known as CB-13)
(36A)	2-(1-Pentyl-2-oxo-1,2-dihydro-3H-indol-3-ylidene)benzohydrazide (also known as N’-(1-Pentyl-2-oxoindolin-3-ylidene)benzohydrazide or BZO-POXIZID or MDA-19 pentyl analogue or 5C-MDA-19) [S 439/2022 wef 01/06/2022]
(37)	2-Phenyl-2-(methylamino)cyclohexanone (also known as Deschloroketamine) [S 283/2021 wef 01/05/2021]
(38)	1-Phenyl-2-phenyl-2-(1-pyrrolidinyl)ethanone (also known as α-Pyrrolidino-2-phenylacetophenone or α-D2PV) [S 439/2022 wef 01/06/2022]
(36AA)	[Deleted by S 750/2020 wef 04/09/2020]
(36B)	[Deleted by S 750/2020 wef 04/09/2020]
(36C)	[Deleted by S 750/2020 wef 04/09/2020]
(37A)	[Deleted by S 750/2020 wef 04/09/2020]
(38AAA)	[Deleted by S 750/2020 wef 04/09/2020]
(38AA)	[Deleted by S 750/2020 wef 04/09/2020]
(38AB)	[Deleted by S 750/2020 wef 04/09/2020]
(38AC)	2-(2-Phenylpropan-2-yl)-5-pentyl-pyrido[4,3-b]indol-1-one (also known as 2-Cumyl-5-pentylgamma-carbolin-1-one or cumyl-PEGACLONE or SGT-151) and its phenylpropyl isomers [S 350/2020 wef 01/05/2020]
(38B)	5-[(2-Phenylpropan-2-yl)-pyrido[4,3-b]indol-1-one-yl]pentanoic acid and its phenylpropyl isomers [S 283/2021 wef 01/05/2021]
(38C)	2-(4-Propoxybenzyl)-5-nitro-1-(2-pyrrolidin-1-ylethyl)-1H-benzo[d]imidazole (also known as protonitazepyne or N-pyrrolidino protonitazene) and its propoxy structural isomers and their respective propoxy positional isomers in the phenyl ring and nitro positional isomers in the 6-membered ring of the benzimidazole structure [S 472/2025 wef 01/07/2025]
(38AD)	[Deleted by S 750/2020 wef 04/09/2020]
(38AE)	[Deleted by S 750/2020 wef 04/09/2020]
(38A)	[Deleted by S 750/2020 wef 04/09/2020]
(39)	Salvinorin A [S 322/2014 wef 01/05/2014]
(40)	2,4,5-Trimethoxy-α-methylphenethylamine (also known as 2,4,5-Trimethoxyamphetamine or TMA-2) and its trimethoxy positional isomers in the phenyl ring [S 283/2021 wef 01/05/2021]

18. Any compound (other than serotonin) structurally derived from 2‑(1H‑indol‑3‑yl)ethanamine (also known as tryptamine) by modification in any of the following ways:

(a)	substitution at the nitrogen atom of the side chain to any extent with alkyl or alkenyl substituents, or by inclusion of only the nitrogen atom of the side chain in a cyclic structure;
(b)	substitution at the carbon atom adjacent to the nitrogen atom of the side chain with alkyl or alkenyl substituents;
(c)	substitution in the 6‑membered ring to any extent with alkyl, alkoxy, haloalkyl, hydroxy, thioalkyl, alkylenedioxy, halide or acetoxy substituents;
(d)	substitution at the 2‑position of the tryptamine ring system with an alkyl substituent,

including any ether, salt or stereoisomeric form of any such compound, any preparation or product containing any such compound, and the following examples of such a compound:

(1)	4‑Acetoxy‑N,N‑diisopropyltryptamine (also known as 4‑Acetoxy‑DiPT or 4‑AcO‑DiPT)
(2)	4‑Acetoxy‑N,N‑dimethyltryptamine (also known as 4‑Acetoxy‑DMT or 4‑AcO‑DMT)
(3)	5‑Benzyloxytryptamine
(4)	5‑Bromo‑N,N‑dimethyltryptamine (also known as 5‑Bromo‑DMT)
(5)	5‑Bromotryptamine
(6)	5‑Chloro‑α‑methyltryptamine (also known as 5‑Chloro‑AMT)
(7)	5‑Chlorotryptamine
(8)	N,N‑Diallyltryptamine
(9)	N,N‑Diethyltryptamine
(10)	N,N‑Diisopropyltryptamine
(10A)	5,6-Dimethoxy-N,N-diisopropyltryptamine (also known as 5,6-Dimethoxy-DiPT or 5,6-MeO-DiPT) [S 430/2024 wef 01/06/2024]
(11)	N,N‑Dimethyltryptamine
(12)	N,N‑Dipropyltryptamine
(13)	Etryptamine
(14)	5‑Fluoro‑N,N‑dimethyltryptamine (also known as 5‑Fluoro‑DMT)
(15)	5‑Fluoro‑α‑methyltryptamine (also known as 5‑Fluoro‑AMT)
(16)	5‑Fluorotryptamine
(17)	4‑Hydroxy‑N,N‑diethyltryptamine (also known as 4‑Hydroxy‑DET or 4‑HO‑DET)
(18)	4‑Hydroxy‑N,N‑diisopropyltryptamine (also known as 4‑Hydroxy‑DiPT or 4‑HO‑DiPT)
(19)	4‑Hydroxy‑N,N‑dimethyltryptamine (also known as Psilocin)
(20)	4‑Hydroxy‑N‑methyl‑N‑ethyltryptamine (also known as 4‑Hydroxy‑MET or 4‑HO‑MET)
(21)	4‑Hydroxy‑N‑methyl‑N‑isopropyltryptamine (also known as 4‑Hydroxy‑MiPT or 4‑HO‑MiPT)
(22)	4‑Hydroxy‑α‑methyltryptamine (also known as 4‑Hydroxy‑AMT or 4‑HO‑AMT)
(23)	5‑Hydroxy‑N‑methyltryptamine (also known as 5‑Hydroxy‑NMT or 5‑HO‑NMT)
(24)	5‑Hydroxy‑N,N‑dimethyltryptamine (also known as Bufotenine)
(25)	5‑Methoxy‑N,N‑diallyltryptamine (also known as 5‑Methoxy‑DALT or 5‑MeO‑DALT)
(26)	5‑Methoxy‑N,N‑diethyltryptamine (also known as 5‑Methoxy‑DET or 5‑MeO‑DET)
(27)	5‑Methoxy‑N,N‑diisopropyltryptamine (also known as 5‑Methoxy‑DiPT or 5‑MeO‑DiPT)
(28)	5‑Methoxy‑N,N‑dimethyltryptamine (also known as 5‑Methoxy‑DMT or 5‑MeO‑DMT)
(29)	5‑Methoxy‑N,N‑dipropyltryptamine (also known as 5‑Methoxy‑DPT or 5‑MeO‑DPT)
(30)	5‑Methoxy‑N‑ethyl‑N‑isopropyltryptamine (also known as 5‑Methoxy‑EiPT or 5‑MeO‑EiPT)
(31)	5‑Methoxy‑N‑ethyl‑N‑propyltryptamine (also known as 5‑Methoxy‑EPT or 5‑MeO‑EPT)
(32)	5‑Methoxy‑α‑ethyltryptamine (also known as 5‑Methoxy‑AET or 5‑MeO‑AET)
(33)	5‑Methoxy‑N‑methyl‑N‑isopropyltryptamine (also known as 5‑Methoxy‑MiPT or 5‑MeO‑MiPT)
(34)	5‑Methoxy‑α‑methyltryptamine (also known as 5‑Methoxy‑AMT or 5‑MeO‑AMT)
(35)	5‑Methoxy‑N‑methyltryptamine (also known as 5‑Methoxy‑NMT or 5‑MeO‑NMT)
(36)	4‑Methyl‑α‑ethyltryptamine (also known as 4‑Methyl‑AET)
(37)	5‑Methyltryptamine
(38)	α‑Methyltryptamine
(39)	N‑Methyltryptamine [S 199/2016 wef 01/05/2016]

19. Any compound structurally derived from indole-3-carboxaldehyde or indole-2-carboxaldehyde by substitution —

(a)

at the nitrogen atom of the indole ring with any of the following:

(i)	an alkyl group;
(ii)	a cyanoalkyl group;
(iii)	an alkenyl group;
(iv)	a cycloalkylmethyl group;
(v)	a cycloalkylethyl group;
(vi)	a 1-(N-methyl-2-piperidinyl)methyl group;
(vii)	a 2-(4-morpholinyl)ethyl group;
(viii)	a 1-(N-methyl-2-pyrrolidinyl)methyl group;
(ix)	a 1-(N-methyl-3-morpholinyl)methyl group;
(x)	a tetrahydropyranylmethyl group;
(xi)	an arylalkyl group; [S 454/2023 wef 01/07/2023]
(xii)	a halogen, hydroxy and/or carboxylic acid derivative of any group mentioned in sub-paragraphs (i) to (xi); and

(b)

at the hydrogen atom of the carboxaldehyde with any of the following:

(i)	an alkyl group;
(ii)	an alkenyl group;
(iii)	an alkylamido group;
(iv)	an alkylcarboxylic acid group;
(v)	a phenyl group;
(vi)	an arylalkyl group; [S 454/2023 wef 01/07/2023]
(vii)	a cycloalkyl group;
(viii)	a cycloalkylmethyl group;
(ix)	a cycloalkylethyl group;
(x)	an adamantyl group;
(xi)	a naphthyl group;
(xii)	a norbornyl group;
(xiii)	a 1,2,3,4-tetrahydronaphthyl group;
(xiv)	a heterocyclic analog of any group mentioned in sub-paragraphs (v) to (xiii),

whether or not the compound is further modified in any of the following ways:

(c)	substitution of the indole ring with a nitrogen heterocyclic analog;
(d)	substitution to the indole ring or its nitrogen heterocyclic analog to any extent;
(e)	substitution to the group mentioned in sub-paragraph (b) to any extent,

including any salt or stereoisomeric form of the compound or derivative of the compound, any preparation or product containing the compound or derivative of the compound, and the following examples of such a compound or derivative:

(1)	[1-(5-Bromopent-1-yl)-1H-indazol-3-yl](naphthalene-1-yl)methanone (also known as 5-Bromo-THJ-018)
(2)	[1-(5-Bromopent-1-yl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (also known as 5-Bromo-UR-144)
(3)	[1-(5-Chloropent-1-yl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (also known as 5-Chloro-THJ-018)
(4)	[1-(5-Chloropent-1-yl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (also known as 5-Chloro-UR-144)
(5)	[1-(4-Fluorobenzyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (also known as FUB-144 or FUB-UR-144)
(6)	[1-(5-Fluoropent-1-yl)-1H-benzimidazol-2-yl](naphthalen-1-yl)methanone (also known as FUBIMINA)
(7)	[1-(5-Fluoropent-1-yl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (also known as THJ-2201)
(8)	[1-(5-Fluoropent-1-yl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (also known as XLR-11 or 5-Fluoro-UR-144)
(9)	[1-(5-Hydroxypent-1-yl)-1H-indazol-3-yl](naphthalen-1-yl)methanone
(10)	[1-(5-Hydroxypent-1-yl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone
(11)	[1-(5-Iodopent-1-yl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (also known as 5-Iodo-THJ-018)
(12)	Naphthalen-1-yl[1-(pent-1-yl)-1H-indazol-3-yl]methanone (also known as THJ-018)
(13)	5-[3-(1-Naphthoyl)-1H-indazol-1-yl]pentanoic acid
(14)	5-[3-(1-Naphthoyl)-1H-indol-1-yl]pentanenitrile (also known as AM-2232)
(15)	(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (also known as UR-144)
(16)	5-[3-(2,2,3,3-Tetramethylcyclopropanecarbonyl)-1H-indol-1-yl]pentanoic acid
(17)	(1-Butyl-1H-indol-3-yl)(naphthalen-1-yl)methanone (also known as JWH-073)
(18)	(4-Chloronaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone (also known as JWH-398)
(19)	[1-(4-Chloropent-1-yl)-1H-indol-3-yl](naphthalen-1-yl)methanone (also known as 4-Chloro-AM-2201)
(20)	(4-Ethylnaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone (also known as JWH-210)
(21)	[1-(5-Fluoropent-1-yl)-1H-indol-3-yl](4-methylnaphthalen-1-yl)methanone (also known as MAM-2201)
(22)	[1-(5-Fluoropent-1-yl)-1H-indol-3-yl](naphthalen-1-yl)methanone (also known as AM-2201)
(23)	[1-(4-Fluoropent-1-yl)-1H-indol-3-yl](naphthalen-1-yl)methanone (also known as 4-Fluoro-AM-2201)
(24)	[1-(5-Fluoropent-1-yl)-6-nitro-1H-indol-3-yl](naphthalen-1-yl)methanone (also known as AM-1235)
(25)	[1-(Heptan-2-yl)-2-methyl-1H-indol-3-yl](naphthalen-1-yl)methanone (also known as JWH-011)
(26)	(1-Heptyl-1H-indol-3-yl)(naphthalen-1-yl)methanone (also known as JWH-020)
(27)	(1-Hexyl-1H-indol-3-yl)(naphthalen-1-yl)methanone (also known as JWH-019)
(28)	(4-Methoxynaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone (also known as JWH-081)
(29)	(2-Methyl-1-propyl-1H-indol-3-yl)(naphthalen-1-yl)methanone (also known as JWH-015)
(30)	(4-Methylnaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone (also known as JWH-122)
(31)	{1-[(1-Methylpiperidin-2-yl)methyl]-1H-indol-3-yl}(naphthalen-1-yl)methanone (also known as AM-1220)
(32)	{1-[2-(Morpholin-4-yl)ethyl]-1H-indol-3-yl}(naphthalen-1-yl)methanone (also known as JWH-200)
(33)	Naphthalen-1-yl[1-(pent-4-en-1-yl)-1H-indol-3-yl]methanone (also known as JWH-022)
(34)	Naphthalen-1-yl(1-pentyl-1H-indol-3-yl)methanone (also known as JWH-018)
(35)	Naphthalen-1-yl(1-propyl-1H-indol-3-yl)methanone (also known as JWH-072)
(36)	2-(2-Chlorophenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone (also known as JWH-203)
(37)	1-[1-(2-Cyclohexylethyl)-1H-indol-3-yl]-2-(2-methoxyphenyl)ethanone (also known as RCS-8)
(38)	2-(2-Methoxyphenyl)-1-{1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}ethanone (also known as cannabipiperidiethanone)
(39)	2-(2-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone (also known as JWH-250)
(40)	2-(3-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone (also known as JWH-302)
(41)	2-(4-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone (also known as JWH-201)
(42)	2-(2-Methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone (also known as JWH-251)
(43)	[1-(5-Fluoropentyl)-1H-indol-3-yl](2-iodophenyl)methanone (also known as AM-694)
(44)	(2-Iodo-5-nitrophenyl){1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}methanone (also known as AM-1241)
(45)	(2-Iodophenyl){1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}methanone (also known as AM-2233)
(46)	(2-Iodophenyl)(1-pentyl-1H-indol-3-yl)methanone (also known as AM-679)
(47)	(4-Methoxyphenyl){2-methyl-1-[2-(morpholin-4-yl)ethyl]-1H-indol-3-yl}methanone (also known as pravadoline)
(48)	(4-Methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone (also known as RCS-4)
(49)	1-Adamantyl{1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}methanone (also known as AM-1248)
(50)	1-Adamantyl(1-pentyl-1H-indol-3-yl)methanone (also known as AB-001) [S 750/2020 wef 04/09/2020]
(51)	(1-(Pent-4-en-1-yl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (also known as XLR-11 N-(4-pentenyl) analogue or UR-144 N-(4-pentenyl) analogue) [S 439/2022 wef 01/06/2022]

20. Any compound structurally derived from indole-3-carboxamide or indole-2-carboxamide by substitution —

(a)

at the nitrogen atom of the indole ring with any of the following:

(i)	an alkyl group;
(ii)	a cyanoalkyl group;
(iii)	an alkenyl group;
(iv)	a cycloalkylmethyl group;
(v)	a cycloalkylethyl group;
(vi)	a 1-(N-methyl-2-piperidinyl)methyl group;
(vii)	a 2-(4-morpholinyl)ethyl group;
(viii)	a 1-(N-methyl-2-pyrrolidinyl)methyl group;
(ix)	a 1-(N-methyl-3-morpholinyl)methyl group;
(x)	a tetrahydropyranylmethyl group;
(xi)	an arylalkyl group; [S 454/2023 wef 01/07/2023]
(xii)	a halogen, hydroxy and/or carboxylic acid derivative of any group mentioned in sub-paragraphs (i) to (xi); and

(b)

at any hydrogen atom of the carboxamide with any of the following:

(i)	an alkyl group;
(ii)	an alkenyl group;
(iii)	an alkylamido group;
(iv)	an alkylcarboxylic acid group;
(v)	a phenyl group;
(vi)	an arylalkyl group; [S 454/2023 wef 01/07/2023]
(vii)	a cycloalkyl group;
(viii)	a cycloalkylmethyl group;
(ix)	a cycloalkylethyl group;
(x)	an adamantyl group;
(xi)	a naphthyl group;
(xii)	a norbornyl group;
(xiii)	a 1,2,3,4-tetrahydronaphthyl group;
(xiv)	a heterocyclic analog of any group mentioned in sub-paragraphs (v) to (xiii),

whether or not the compound is further modified in any of the following ways:

(c)	substitution of the indole ring with a nitrogen heterocyclic analog;
(d)	substitution to the indole ring or its nitrogen heterocyclic analog to any extent;
(e)	substitution to the group mentioned in sub-paragraph (b) to any extent,

(1)	N-(1-Adamantyl)-1-(5-bromopentyl)-1H-indazole-3-carboxamide (also known as 5-Bromo-APINACA or 5-Bromo-AKB48)
(2)	N-(1-Adamantyl)-1-(5-chloropentyl)-1H-indazole-3-carboxamide (also known as 5-Chloro-APINACA or 5-Chloro-AKB48)
(3)	N-(1-Adamantyl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (also known as Adamantyl CHMINACA or SGT-37)
(4)	N-(1-Adamantyl)-1-(5-hydroxypentyl)-1H-indazole-3-carboxamide
(5)	N-(1-Adamantyl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (also known as FUB-APINACA or FUB-AKB48)
(5A)	N-(1-Adamantyl)-1-(4-fluorobutyl)-1H-indazole-3-carboxamide (also known as 4-Fluoro-ABUTINACA or 4F-ABUTINACA or 4-Fluoro ABINACA) [S 283/2021 wef 01/05/2021]
(6)	N-(1-Adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (also known as 5-Fluoro-APINACA or 5F-AKB48)
(7)	N-(1-Adamantyl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (also known as 5-Fluoro-APICA or STS-135)
(7A)	N-(1-Adamantyl)-4-hydroxybutyl-1H-indazole-3-carboxamide [S 283/2021 wef 01/05/2021]
(8)	N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide (also known as APINACA)
(9)	N-(1-Adamantyl)-1-pentyl-1H-indole-3-carboxamide (also known as APICA)
(9A)	4-{3-[(1-Adamantyl)carbamoyl]-1H-indazole-1-yl}butanoic acid [S 439/2022 wef 01/06/2022]
(10)	N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (also known as MAB-CHMINACA or ADB-CHMINACA)
(10A)	N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4,5-dihydroxypentyl)-1H-indazole-3-carboxamide [S 430/2024 wef 01/06/2024]
(11)	N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (also known as N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-[(4-fluorophenyl)]methyl-1H-indazole-3-carboxamide or ADB-FUBINACA)
(12)	N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (also known as 5-Fluoro-ADB-PINACA)
(13)	N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (also known as 5-Fluoro-ADBICA)
(13A)	N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-hydroxycyclohexylmethyl)-1H-indazole-3-carboxamide [S 430/2024 wef 01/06/2024]
(13B)	N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(pent-4-en-1-yl)-1H-indazole-3-carboxamide (also known as ADB-4en-PINACA, ADMB-4en-PINACA or ADB-PENINACA) [S 430/2024 wef 01/06/2024]
(14)	N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (also known as ADB-PINACA)
(15)	N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide (also known as ADBICA)
(15A)	4-{3-[(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)carbamoyl]-1H-indazole-1-yl}butanoic acid [S 283/2021 wef 01/05/2021]
(16)	N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-chloropentyl)-1H-indazole-3-carboxamide (also known as 5-Chloro-AB-PINACA)
(17)	N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (also known as AB-CHMINACA)
(18)	N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (also known as N-[1-amino-3-methyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide or AB-FUBINACA)
(19)	N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indole-3-carboxamide (also known as AB-FUBICA)
(20)	N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (also known as 5-Fluoro-AB-PINACA)
(21)	N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (also known as AB-PINACA)
(22)	N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (also known as PX-3 or APP-CHMINACA)
(23)	N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (also known as PX-2 or 5-Fluoro-APP-PINACA)
(24)	N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (also known as PX-1 or 5-Fluoro-APP-PICA)
(24A)	2-[1-(Cyclohexylmethyl)-1H-indazole-3-carboxamido]-3-methylbutanoic acid [S 472/2025 wef 01/07/2025]
(25)	Ethyl 2-[1-(4-fluorobenzyl)-1H-indazole-3-carboxamido]-3-methylbutanoate (also known as EMB-FUBINACA or AEB-FUBINACA or FUB-AEB)
(26)	Ethyl 2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (also known as 5-Fluoro-EDMB-PINACA)
(27)	Ethyl 2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3-methylbutanoate (also known as 5-Fluoro-AEB or 5-Fluoro-EMB-PINACA)
(28)	2-[1-(4-Fluorobenzyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoic acid
(29)	2-[1-(4-Fluorobenzyl)-1H-indazole-3-carboxamido]-3-methylbutanoic acid
(30)	2-[1-(4-Fluorobenzyl)-1H-indole-3-carboxamido]-3-methylbutanoic acid
(31)	2-[1-(4-Fluorobutyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoic acid
(31A)	2-[1-(4-Fluorobutyl)-1H-indole-3-carboxamido]-3,3-dimethylbutanoic acid [S 283/2021 wef 01/05/2021]
(32)	5-Fluoropent-1-yl-N-naphthalen-1-yl-1H-indole-3-carboxamide (also known as CBM-2201, 5-Fluoro-NNEI, 5F-NNEI or MN-24F)
(33)	1-(5-Fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide (also known as 5-Fluoro-cumyl-PICA)
(34)	2-[1-(5-Fluoropentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoic acid
(35)	2-[1-(5-Fluoropentyl)-1H-indole-3-carboxamido]-3,3-dimethylbutanoic acid
(36)	2-[1-(5-Fluoropentyl)-1H-indazole-3-carboxamido]-3-methylbutanoic acid
(36AA)	2-[1-(5-Fluoropentyl)-1H-indole-3-carboxamido]-3-methylbutanoic acid [S 439/2022 wef 01/06/2022]
(36A)	2-[1-(5-Fluoropentyl)-1H-indole-3-carboxamido]-3-phenylpropanoic acid [S 283/2021 wef 01/05/2021]
(36B)	1-(5-Hydroxypentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide [S 283/2021 wef 01/05/2021]
(36C)	Methyl 2-(1-butyl-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (also known as MDMB-BUTINACA or MDMB-BINACA [S 430/2024 wef 01/06/2024]
(37)	Methyl 2-[1-(cyclohexylmethyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (also known as MDMB-CHMINACA)
(38)	Methyl 2-[1-(cyclohexylmethyl)-1H-indazole-3-carboxamido]-3-methylbutanoate (also known as MA-CHMINACA)
(39)	Methyl 2-[1-(cyclohexylmethyl)-1H-indole-3-carboxamido]-3,3-dimethylbutanoate (also known as Methyl N-{[1-(cyclohexylmethyl)-1H-indol-3-yl]carbonyl}-3-methyl-L-valinate or MDMB-CHMICA)
(40)	Methyl 2-[1-(cyclohexylmethyl)-1H-indole-3-carboxamido]-3-methylbutanoate (also known as MMB-CHMICA)
(41)	Methyl 3,3-dimethyl-2-[1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido]butanoate (also known as MDMB-4en-PINACA or MDMB-PINACA N1-pentyl-4-en isomer or MDMB(N)-022)
(42)	Methyl 2-[1-(4-fluorobenzyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (also known as MDMB-FUBINACA)
(43)	Methyl 2-[1-(4-fluorobenzyl)-1H-indazole-3-carboxamido]-3-methylbutanoate (also known as Methyl 2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate or MMB-FUBINACA or AMB-FUBINACA or FUB-AMB)
(44)	Methyl 2-[1-(4-fluorobenzyl)-1H-indole-3-carboxamido]-3-methylbutanoate (also known as MMB-FUBICA or AMB-FUBICA)
(45)	Methyl 2-[1-(4-fluorobutyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (also known as Methyl 2-{[1-(4-fluorobutyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate, 4F-MDMB-BINACA, 4F-MDMB-BUTINACA or 4-Fluoro-MDMB-BINACA)
(46)	Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (also known as 5-Fluoro-MDMB-PINACA or 5-Fluoro-ADB)
(47)	Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3-methylbutanoate (also known as Methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3-methylbutanoate, 5F-AMP, 5-Fluoro-AMP, 5F-MMB-PINACA, 5F-AMB-PINACA, 5-Fluoro-AMB or 5-Fluoro-MMB-PINACA)
(48)	Methyl 2-[1-(5-fluoropentyl)-1H-indole-3-carboxamido]-3,3-dimethylbutanoate (also known as Methyl 2-{[1-(5-fluoropentyl)-1H-indole-3-carbonyl]amino}-3,3-dimethylbutanoate, 5F-MDMB-PICA, 5F-MDMB-2201, 5-Fluoro-MDMB-2201 or 5-Fluoro-MDMB-PICA)
(49)	Methyl 2-[1-(5-fluoropentyl)-1H-indole-3-carboxamido]-3-phenylpropanoate (also known as 5-Fluoro-MPP-PICA or 5-Fluoro-MPhP-PICA or MPHP-2201)
(50)	Methyl 2-[1-(4-hydroxybutyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate
(51)	Methyl 2-[1-(5-hydroxypentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate
(51A)	Methyl 2-[1-(5-hydroxypentyl)-1H-indole-3-carboxamido]-3-phenylpropanoate [S 283/2021 wef 01/05/2021]
(52)	N-(1-Methyl-1-phenylethyl)-1-(4-cyanobutyl)-1H-indazole-3-carboxamide (also known as 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide or Cumyl-4CN-BINACA or 4-Cyano cumyl-butinaca or SGT-78)
(53)	N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H-indazole-3-carboxamide (also known as 2-[(1-Butyl-1H-indazol-3-yl)formamido]-3,3-dimethylbutanamide or ADB-BUTINACA)
(54)	1-Pentyl-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide (also known as Cumyl-PICA)
(55)	5-{3-[(1-Adamantyl)carbamoyl]-1H-indazole-1-yl}pentanoic acid
(56)	5-{3-[(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)carbamoyl]-1H-indazole-1-yl}pentanoic acid
(57)	5-{3-[(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)carbamoyl]-1H-indole-1-yl}pentanoic acid
(58)	5-{3-[(1-Amino-3-methyl-1-oxobutan-2-yl)carbamoyl]-1H-indazole-1-yl}pentanoic acid
(59)	4-{3-[(2-Phenylpropan-2-yl)carbamoyl]-1H-indazole-1-yl}butanoic acid [S 283/2021 wef 01/05/2021]
(60)	2-[1-(Pent-4-en-1-yl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoic acid
(61)	2-[1-(4,5-Dihydroxypentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoic acid
(62)	2-(1-Butyl-1H-indazole-3-carboxamido)-3,3-dimethylbutanoic acid
(63)	N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-hydroxybutyl)-1H-indazole-3-carboxamide
(64)	5-{3-[(2-Phenylpropan-2-yl)carbamoyl]-1H-indol-1-yl}pentanoic acid
(65)	1-(5-Fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (also known as 5-Fluoro-cumyl-PINACA)
(66)	Ethyl 2-[1-(5-fluoropentyl)-1H-indole-3-carboxamido]-3-methylbutanoate (also known as 5-Fluoro-EMB-PICA or EMB-2201)
(67)	Methyl 2-[1-(4-fluorobutyl)-1H-indole-3-carboxamido]-3,3-dimethylbutanoate (also known as Methyl 2-{[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino}-3,3-dimethylbutanoate, 4F-MDMB-BICA, 4F-MDMB-BUTICA or 4-Fluoro-MDMB-BUTICA) [S 750/2020 wef 04/09/2020]

21. Any compound structurally derived from indole-3-carboxylic acid or indole-2-carboxylic acid by substitution —

(a)

at the nitrogen atom of the indole ring with any of the following:

(i)	an alkyl group;
(ii)	a cyanoalkyl group;
(iii)	an alkenyl group;
(iv)	a cycloalkylmethyl group;
(v)	a cycloalkylethyl group;
(vi)	a 1-(N-methyl-2-piperidinyl)methyl group;
(vii)	a 2-(4-morpholinyl)ethyl group;
(viii)	a 1-(N-methyl-2-pyrrolidinyl)methyl group;
(ix)	a 1-(N-methyl-3-morpholinyl)methyl group;
(x)	a tetrahydropyranylmethyl group;
(xi)	an arylalkyl group; [S 454/2023 wef 01/07/2023]
(xii)	a halogen, hydroxy and/or carboxylic acid derivative of any group mentioned in sub-paragraphs (i) to (xi); and

(b)

at the hydrogen atom of the carboxylic acid with any of the following:

(i)	an alkyl group;
(ii)	an alkenyl group;
(iii)	an alkylamido group;
(iv)	an alkylcarboxylic acid group;
(v)	a phenyl group;
(vi)	an arylalkyl group; [S 454/2023 wef 01/07/2023]
(vii)	a cycloalkyl group;
(viii)	a cycloalkylmethyl group;
(ix)	a cycloalkylethyl group;
(x)	an adamantyl group;
(xi)	a naphthyl group;
(xii)	a norbornyl group;
(xiii)	a 1,2,3,4-tetrahydronaphthyl group;
(xiv)	a heterocyclic analog of any group mentioned in sub-paragraphs (v) to (xiii),

whether or not the compound is further modified in any of the following ways:

(c)	substitution of the indole ring with a nitrogen heterocyclic analog;
(d)	substitution to the indole ring or its nitrogen heterocyclic analog to any extent;
(e)	substitution to the group mentioned in sub-paragraph (b) to any extent,

(1)	Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indazole-3-carboxylate (also known as 5-Fluoro-SDB-005)
(2)	Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (also known as NM-2201 or CBL-2201)
(3)	Naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate (also known as SDB-005)
(4)	Quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-carboxylate (also known as BB-22 or QUCHIC)
(5)	Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (also known as 5-Fluoro-PB-22 or 5-Fluoro-QUPIC)
(6)	Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (also known as PB-22 or QUPIC) [S 750/2020 wef 04/09/2020]

[S 939/2021 wef 15/12/2021]

22. With effect from 1 September 2025 to 30 April 2026 (both dates inclusive), the following compounds, including any salt or stereoisomeric form of such compounds, and any preparation or product containing such compounds:

(1)	Butyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate (also known as butomidate) and its butyl structural isomers (namely isobutomidate, sec-butomidate and tert-butomidate)
(2)	Isopropyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate (also known as isopropoxate)
(3)	Propyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate (also known as propoxate)
(4)	2,2,2-Trifluoroethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate (also known as trifluoro-etomidate or TF-etomidate)

[S 557/2025 wef 01/09/2025]

[S 77/2026 wef 28/02/2026]

FIFTH SCHEDULE

Regulation 14

Form of Register

Part I

Entries to be Made in Case of Obtaining

Date on which supply received

NAME

ADDRESS

Amount obtained

Form in which obtained

Of person or firm from whom obtained

Part II

Entries to be Made in Case of Supply

Date on which the transaction was effected

NAME

ADDRESS

Particulars as to licence or authority of person or firm supplied to be in possession

Amount supplied

Form in which supplied

Stock balance (receipts to be added in red ink)

Of person or firm supplied

SIXTH SCHEDULE

Regulation 14

Form of Register for Wards, Theatres and Other Departments in Hospitals

Controlled Drug Stock Sheet

Ward No.

Name of Controlled Drug

Registration Patient’s Admission No.

Date Received from
Disp./ given to patient

Patient’s name in block letters according to N.R.I.C.

Amount

Checked by

Given by

Remarks

Rec’d

Used

Bal.

SEVENTH SCHEDULE

Regulation 4(2)

Fees for Licences

First column

Second column

1.	Licence to sell controlled drugs by wholesale

$560 per year

2.	Licence to manufacture controlled drugs

$560 per year

3.	Licence to import controlled drugs

$111

4.	Licence to export controlled drugs

$111

5.	Amendment to any licence on any single occasion —

(a)	with site inspection

$220

(b)	without site inspection

$57.

[S 487/2024 wef 01/07/2024]

[S 464/2022 wef 01/07/2022]

[S 108/2007 wef 13/03/2007]

[S 88/2019 wef 02/04/2019]

LEGISLATIVE HISTORY

Misuse of Drugs Regulations

This Legislative History is provided for the convenience of users of the Misuse of Drugs Regulations. It is not part of these Regulations.

G. N. No. S 234/1973—Misuse of Drugs Regulations 1973

Date of commencement

7 July 1973

G. N. No. S 47/1974—Misuse of Drugs (Amendment) Regulations 1974

Date of commencement

15 February 1974

G. N. No. S 60/1975—Misuse of Drugs (Amendment) Regulations 1975

Date of commencement

27 March 1975

G. N. No. S 186/1976—Misuse of Drugs (Amendment) Regulations 1976

Date of commencement

17 September 1976

G. N. No. S 13/1978—Misuse of Drugs (Amendment) Regulations 1978

Date of commencement

27 January 1978

G. N. No. S 89/1979—Misuse of Drugs (Amendment) Regulations 1979

Date of commencement

20 April 1979

G. N. No. S 177/1981—Misuse of Drugs (Amendment) Regulations 1981

Date of commencement

29 May 1981

G. N. No. S 358/1982—Misuse of Drugs (Amendment) Regulations 1982

Date of commencement

1 January 1983

G. N. No. S 237/1983—Misuse of Drugs (Amendment) Regulations 1983

Date of commencement

4 October 1983

10.

G. N. No. S 228/1984—Misuse of Drugs (Amendment) Regulations 1984

Date of commencement

31 August 1984

11.

G. N. No. S 337/1984—Misuse of Drugs (Amendment No. 2) Regulations 1984

Date of commencement

1 January 1985

12.

G. N. No. S 30/1986—Misuse of Drugs (Amendment) Regulations 1986

Date of commencement

7 February 1986

13.

G. N. No. S 209/1986—Misuse of Drugs (Amendment No. 2) Regulations 1986

Date of commencement

15 August 1986

14.

G. N. No. S 49/1990—Misuse of Drugs (Amendment) Regulations 1990

(G.N. No. S 67/1990 — Corrigendum)

Date of commencement

15 February 1990

15.

G. N. No. S 565/1991—Misuse of Drugs (Amendment) Regulations 1991

Date of commencement

2 January 1992

16.

G. N. No. S 65/1992—Misuse of Drugs (Amendment) Regulations 1992

Date of commencement

1 March 1992

17.

1990 Revised Edition—Misuse of Drugs Regulations

Date of operation

25 March 1992

18.

G. N. No. S 278/1992—Misuse of Drugs (Amendment No. 2) Regulations 1992

Date of commencement

1 July 1992

19.

G. N. No. S 491/1993—Misuse of Drugs (Amendment) Regulations 1993

Date of commencement

10 December 1993

20.

G. N. No. S 222/1996—Misuse of Drugs (Amendment) Regulations 1996

Date of commencement

17 May 1996

21.

G. N. No. S 389/1997—Misuse of Drugs (Amendment) Regulations 1997

Date of commencement

1 October 1997

22.

1999 Revised Edition—Misuse of Drugs Regulations

Date of operation

1 July 1999

23.

G. N. No. S 390/1999—Misuse of Drugs (Amendment No. 2) Regulations 1999

Date of commencement

9 September 1999

24.

G. N. No. S 231/2000—Misuse of Drugs (Amendment) Regulations 2000

Date of commencement

15 May 2000

25.

G. N. No. S 436/2000—Misuse of Drugs (Amendment No. 2) Regulations 2000

Date of commencement

2 October 2000

26.

G. N. No. S 140/2001—Misuse of Drugs (Amendment) Regulations 2001

Date of commencement

1 April 2001

27.

G. N. No. S 492/2001—Misuse of Drugs (Amendment No. 2) Regulations 2001

Date of commencement

8 October 2001

28.

G. N. No. S 506/2005—Misuse of Drugs (Amendment) Regulations 2005

Date of commencement

1 August 2005

29.

G. N. No. S 490/2006—Misuse of Drugs (Amendment) Regulations 2006

Date of commencement

14 August 2006

30.

G. N. No. S 108/2007—Misuse of Drugs (Amendment) Regulations 2007

Date of commencement

13 March 2007

31.

G. N. No. S 525/2010—Misuse of Drugs (Amendment) Regulations 2010

Date of commencement

20 September 2010

32.

G. N. No. S 684/2010—Misuse of Drugs (Amendment No. 2) Regulations 2010

Date of commencement

15 November 2010

33.

G. N. No. S 270/2013—Misuse of Drugs (Amendment) Regulations 2013

Date of commencement

1 May 2013

34.

G. N. No. S 322/2014—Misuse of Drugs (Amendment) Regulations 2014

Date of commencement

1 May 2014

35.

G. N. No. S 571/2014—Misuse of Drugs (Amendment No. 2) Regulations 2014

Date of commencement

1 September 2014

36.

G. N. No. S 253/2015—Misuse of Drugs (Amendment) Regulations 2015

Date of commencement

1 May 2015

37.

G. N. No. S 199/2016—Misuse of Drugs (Amendment) Regulations 2016

Date of commencement

1 May 2016

38.

G. N. No. S 193/2017—Misuse of Drugs (Amendment) Regulations 2017

Date of commencement

1 May 2017

39.

G. N. No. S 234/2018—Misuse of Drugs (Amendment) Regulations 2018

Date of commencement

1 May 2018

40.

G. N. No. S 588/2018—Misuse of Drugs (Amendment No. 2) Regulations 2018

Date of commencement

1 October 2018

41.

G. N. No. S 151/2019—Misuse of Drugs (Amendment No. 2) Regulations 2019

Date of commencement

25 March 2019

42.

G. N. No. S 88/2019—Misuse of Drugs (Amendment) Regulations 2019

Date of commencement

2 April 2019

43.

G. N. No. S 353/2019—Misuse of Drugs (Amendment No. 3) Regulations 2019

Date of commencement

1 May 2019

44.

G.N. No. S 791/2019—Misuse of Drugs (Amendment No. 4) Regulations 2019

Date of commencement

1 December 2019

45.

G.N. No. S 350/2020—Misuse of Drugs (Amendment) Regulations 2020

Date of commencement

1 May 2020

46.

G.N. No. S 750/2020—Misuse of Drugs (Amendment No. 2) Regulations 2020

Date of commencement

4 September 2020

47.

G.N. No. S 283/2021—Misuse of Drugs (Amendment) Regulations 2021

Date of commencement

1 May 2021

48.

G.N. No. S 939/2021—Misuse of Drugs (Amendment No. 2) Regulations 2021

Date of commencement

15 December 2021

49.

G.N. No. S 439/2022—Misuse of Drugs (Amendment) Regulations 2022

Date of commencement

1 June 2022

50.

G.N. No. S 464/2022—Misuse of Drugs (Amendment No. 2) Regulations 2022

Date of commencement

1 July 2022

51.

G.N. No. S 399/2023—Misuse of Drugs (Amendment) Regulations 2023

Date of commencement

26 June 2023

52.

G.N. No. S 454/2023—Misuse of Drugs (Amendment No. 2) Regulations 2023

Date of commencement

1 July 2023

53.

G.N. No. S 430/2024—Misuse of Drugs (Amendment) Regulations 2024

Date of commencement

1 June 2024

54.

G.N. No. S 487/2024—Misuse of Drugs (Amendment No. 2) Regulations 2024

Date of commencement

1 July 2024

55.

G.N. No. S 472/2025—Misuse of Drugs (Amendment) Regulations 2025

Date of commencement

1 July 2025

56.

G.N. No. S 557/2025—Misuse of Drugs (Amendment No. 2) Regulations 2025

Date of commencement

1 September 2025

57.

G.N. No. S 796/2025—Misuse of Drugs (Amendment No. 3) Regulations 2025

Date of commencement

15 December 2025

58.

G.N. No. S 77/2026—Misuse of Drugs (Amendment) Regulations 2026

Date of commencement

28 February 2026